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Abstract
G-CSF is routinely used to treat neutropenia/leukopenia or to increase
hematopoietic stem cell generation in bone marrow donors. G-CSF and its
receptor, G-CSFR, are produced by various cell types both in the peripheral
circulation and within brain. As a consequence, exogenous administration of GCSF results in a broad spectrum of effects involving hematopoietic, immune and
central nervous systems.
G-CSF administration in a mouse model of Alzheimer’s disease (AD) has
revealed both cognitive benefits and disease modifying effects: a) decreased Aβ
plaque burden, b) increased microgliosis, c) increased neurogenesis and d)
improved performance in radial arm water maze (RAWM). In clinical studies, GCSF plasma levels were found to be lower in patients with early AD in
comparison to healthy age matched controls. A course of G-CSF administration
in humans is known to increase levels of circulating hematopoietic stem cells
(CD34 cells), monocytes and neutrophils in patients with neutropenia and when
administered to patients with AD, there is also a similar increase in absolute
monocyte count, CD34 cells and total neutrophils. The extent to which the
beneficial effects of G-CSF in AD depend on monocyte infiltration into CNS,
compared to direct neurotrophic actions of G-CSF on the CNS, is not known.
The overall goal of this study was to investigate and understand the
effects of G-CSF in an AD mouse model, but more specifically to distinguish the
viii

actions of G-CSF that affect the peripheral monocyte population from the direct
actions on CNS. The first approach was to examine in vitro effects of G-CSF
within a monocytic cell line (THP-1) and a neuronal cell line (SH-SY5Y). The
second approach was to study effects of G-CSF on infiltration of bone marrowderived cells into the brain by utilizing a chimeric GFP+ APP/PS1 AD mouse
model. The third approach was to assess the effects of G-CSF on hippocampal
neurogenesis in both a wild-type and AD mouse model.
Comparison of the monocytic and neuronal cell lines showed a) G-CSF
interacts with its cognate receptor with different binding kinetics and with a
greater affinity for the monocyte G-CSFR, b) the number of G-CSF receptors in
neurons is greater than in monocytes, and c) the anti-apoptotic response in
neurons occurs at lower concentrations of G-CSF than in monocytes. Various
concentrations of G-CSF increased proliferation of both the monocytic and
neuronal cell line in vitro. G-CSF did not improve migratory properties of the
monocytic cell line, either adhesiveness or migration through a membrane.
In vivo G-CSF treatment (250μg/kg s.c. qod for 2 ½ weeks) in both the AD
chimeric and non-chimeric AD mice resulted in increased microgliosis and
decreased amyloid plaque burden in the hippocampus. In the chimeric AD mice,
G-CSF treatment did not increase infiltration of GFP+ bone marrow derived cells
(BMDC) into brain parenchyma and did not increase adhesion to
microvasculature. In the non-chimeric AD mice there was improvement of
neurogenesis to non-transgenic levels after G-CSF treatment and an increase in
synaptogenesis in the CA1 region of the hippocampus.

ix

The effects of G-CSF on the endogeneous microglial population are most
likely responsible for the increase in microgliosis, as no significant increase of
BMDC infiltration into the brain parenchyma was found in vivo. The enhanced
proliferation and improved viability of the neuronal cell line after G-CSF treatment
may explain the improvement in neurogenesis and significant increase in
synaptogenesis seen in the AD mouse model. The actions of G-CSF on neural
stem/progenitor cells to stimulate hippocampal neurogenesis and to enhance
resident microglial capacity to decrease amyloid burden are the most likely
mechanisms responsible for the behavioral improvement seen in the AD mouse
model.
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Chapter 1: Introduction
Note to Reader
Portions of this introduction have been previously published (Rowe et al.,
2009) and are utilized with permission of the publisher.
Alzheimer’s Disease (AD) is a progressive neurodegenerative disease
causing problems with memory, thinking and behavior severe enough to affect
work, lifelong hobbies or social life. Patients with AD lose the ability to encode
new memories. AD is also characterized by synaptic loss in the hippocampus
and association cortices, which more strongly correlates to the overall cognitive
decline, than β-amyloid plaque and neurofibrillary tangle development (Selkoe,
2002).
AD is the sixth‐leading cause of death in the United States and the fifth
leading cause in death of those over the age of sixty-five years old (AlzheimersAssociation, 2011). AD gets worse over time, it is fatal and there is currently no
cure. Without the emergence of new treatments, AD threatens to become a
pandemic. According to a 2011 study, Alzheimer’s Disease Facts and Figures
there are now more than five million people in the United States living with AD.
One in eight people aged 65 and older have AD. Most people survive an average
of four to eight years after an Alzheimer’s diagnosis, but some live as long as
twenty years with the disease. Without a cure or effective treatments to delay the
1

onset or progression of Alzheimer’s disease, the prevalence would grow to 7.7
million people with the disease by 2030 and is expected to soar to approximately
16 million by mid‐century. AD is the only cause of death among the top 10 in
America without a way to prevent, cure, or even slow its progression
(Alzheimers-Association, 2011).
Neuropathology
The pathological hallmarks of AD are extracellular β-amyloid plaques,
intracellular neurofibrillary tangles, and neurodegeneration in areas of the brain
important for learning and memory, such as the hippocampus, the entorhinal
cortex and other associated cortices (DeKosky et al., 1996). Major risk factors
include age and Apo-E-epsilon 4 (APOE4) (Swaab et al., 2002). APOE4 reduces
age of onset of AD most likely due to dysfunctional clearance of β-amyloid; as
those with APOE4 have less overall apolipoprotein activity than those with
APOE2 or APOE3 allele (Corder et al., 1993, Rebeck et al., 1993, Rebeck et al.,
1994, Kim et al., 2009).
In the dysregulation of the metabolism of β-amyloid precursor protein
(APP) in AD; APP is broken down by two proteases or enzymes, β and γ
secretase (Li et al., 2000), into β-amyloid peptides, Aβ 1-40 and Aβ 1-42
respectively (Hardy and Selkoe, 2002), and then form extracellular fibrils and βpleated sheets which eventually result in aggregation into plaques within the
brain (Selkoe, 2000). The overproduction and eventual deposition of Aβ currently
is regarded as the crucial step for the development of AD (Selkoe, 2000). Aβ is
considered toxic both in vitro and in vivo, resulting in DNA damage, apoptosis,
2

and axonal damage, which lead eventually to neuronal death or
neurodegeneration (Paradis et al., 1996, Naslund et al., 2000, Vickers et al.,
2000). β-amyloid deposition begins ten to twenty years prior to the appearance of
clinical dementia (Naslund et al., 2000, Blasko and Grubeck-Loebenstein, 2003).
It is not only important to inhibit the production of toxic Aβ, but also to clear the βamyloid deposits to mitigate the neurodegeneration and cognitive deficits found
in AD.
Intraneuronal neurofibrillary tangles (NFT) are composed of abnormally
folded and hyperphosphorylated tau, a protein involved in microtubule formation
(Blasko and Grubeck-Loebenstein, 2003). The presence of NFT in AD has been
shown to be induced by Aβ plaques. This is thought to be carried out by the
hyperphosphorylation of the tau protein by the enzyme glycogen synthase
kinase-3 beta (GSK-3β) which causes destabilization of the cytoskeleton
resulting in the cell death seen in AD (Ishizawa et al., 2003, Jamsa et al., 2004).
The presence of NFT is another mandatory pathology for the diagnosis of
AD (Braak et al., 1993, Jellinger, 1998, Hardy and Selkoe, 2002, Blasko and
Grubeck-Loebenstein, 2003). The appearance of NFT in the AD brain occurs
after β-amyloid deposition has already begun (Hardy and Selkoe, 2002).
Neuropathological Staging
AD pathology can be separated into different stages of propagation
dependent on the location of neurofibrillary changes (tangle-bearing neurons)
and the severity of the changes within the brain. The first two stages (Stage 1 &
2) are considered transentorhinal, which are the clinically silent cases. The
3

middle two stages (Stage 3 & 4) are the limbic stages, which include the
hippocampus and temporal lobe, early AD. The final two stages (Stage 5 & 6) are
called the isocortical or neocortical stages, which include the cingulate and
angular cortices, and are consistent with fully developed AD (Braak and Braak,
1991, 1995, Nagy et al., 1998).
Clinical stages of Alzheimer’s Disease
AD symptoms may vary between patient, and an individual patient may
switch between various stages of AD throughout the course of the disease, but
the stages provide a general idea of how abilities change during the course of the
disease. In stage 1, there is no noticeable impairment. In stage 2, there is a very
mild cognitive decline, which may be noticeable to the individual, but not to the
clinician or the friends and family. In stage 3, there is a mild cognitive decline that
becomes noticeable to others and early stage AD may be diagnosed at this point.
In stage 4, there is a moderate cognitive decline, which can be diagnosed on
clinical exam and mild or early-stage AD can be diagnosed at this point. In stage
5, there is a moderately severe decline, cognitive impairment is apparent and the
patient probably will need assistance with activities of daily living and therefore
the diagnosis is moderate or mid-stage AD. In stage 6, there is a severe
cognitive decline and personality changes may arise, moderately severe or midstage AD. Finally in stage 7, there is a very severe cognitive decline in which
patient’s no longer respond to environmental stimuli and are dependent on others
for all activities of daily living, severe or late-stage AD (Alzheimers-Association,
2007).
4

FDA approved treatments for Alzheimer’s Disease
There are no effective treatments that reverse or delay the
neurodegeneration or decrease in cognition seen in AD patients. As neurons in
the AD brain are assaulted by toxic Aβ as well as inflammatory cytokines from
activated glial cells, they result in diminished neuronal metabolism and
disturbances of multiple transmitter systems, such as loss of cholinergic neurons
in the basal forebrain. The current FDA approved AD treatment regimens
temporarily assist in alleviating this deficit of neuronal transmitters.
The current treatment of acetylcholinesterase inhibitors (AChE-I) increase
levels of synaptic acetylcholine (ACh), such as Donepezil, Galantamine and
Rivastigmine, and therefore temporarily improves memory function by increasing
levels of acetylcholine in the brain; these are used in early to moderate stages of
AD, although Donepezil can also be used in the severe stage of AD. Another
drug class used is NMDA glutamate receptor antagonists, such as Memantine,
which also acts by improving memory function, by protecting glutamatergic
neurons from excess glutamate; this is used in moderate to severe stages of AD
and can also be used in conjunction with Donepezil. These treatments help
alleviate the early symptoms caused by the loss or dysfunction of cholinergic and
glutamatergic neurons or synapses. Current standard treatments regimens delay
the worsening of symptoms temporarily but do not alter the course of the
disease.

5

Circuitry of the hippocampus
The hippocampus is important in encoding or the formation of long-term
memories, while the parahippocampal region, including the entorhinal cortex,
solidifies these memories (Eichenbaum, 2000).The entorhinal cortex (EC)
projects to the dendrites of the granular zone (GZ) of the dentate gyrus (DG) in
the hippocampus (HC) via the perforant pathway. The GZ projects to the
pyramidal neurons in the CA3 region of the HC via mossy fibers. The CA3 region
projects contra-laterally to the CA1 region of the HC via the associational
commissural pathway and projects ipsilaterally to the CA1 region via the Shaffer
collateral pathway. The CA1 region projects to the subiculum which projects to
the EC. Long term potentiation (LTP) is comprised of the perforant pathway,
mossy fibers and Schaffer collaterals, which may require simultaneous pre and
post synaptic activity for LTP, or long-term memory storage, to occur (Bliss and
Gardner-Medwin, 1973, Bliss and Lomo, 1973, Kandel and Pittenger, 1999). The
circuitry between the HC and EC is important in encoding long-term memories,
and LTP is impaired in AD, therefore the effects on this region of the brain are
important when studying AD (Rowan et al., 2003).
Neurogenesis in the adult brain
Specific regions of adult brain retain the capacity to generate new neurons
throughout life. These neuro-anatomic regions house neural stem cells in a
micro-environment (neurogenic niche) appropriate for generation, of new
neurons (McKay, 1997, Cameron and McKay, 1998, Eriksson et al., 1998,
Kempermann et al., 1998, Gage, 2000). Neurogenic niches are localized both in
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the subventricular zone (SVZ) of the anterior lateral ventricles and the
subgranular zone (SGZ) of the DG of the HC.
Not only can NSC be produced by the brain endogenously, but it has been
reported that bone marrow stem cells (BMSC) can differentiate into glial cells,
such as microglia (Simard and Rivest, 2004), or neuronal-like cells in the brain
(Brazelton et al., 2000). Our laboratory has been studying bone marrow derived
cells (BMDC) as a potential source of neurons for treatment of neurologic
diseases over the last 10 years. BMDC have been shown to differentiate into
neural cells in vitro and in vivo migrate to the brain where they can differentiate
into neurons or glial cells, such as microglia (Brazelton et al., 2000, Mezey et al.,
2000, Sanchez-Ramos et al., 2000, Woodbury et al., 2000, Simard et al., 2006).
Both BMSC, that express nestin, and adult brain NSC may become cells with the
morphological, immunocytochemical (ICC), and functional characteristics of
neurons (Song et al., 2007). Although in comparison to the amount of microglia
derived from BMSC the amount of neuronal cells derived from BMSC is less,
only 0.2-0.3% of total neurons (Brazelton et al., 2000). The exact mechanism of
the transdifferentiation of BMDC to neural cells is unclear although may reflect
their ability to fuse with injured neurons (Weimann et al., 2003). In vivo studies
suggest that generation of new neurons from a BMDC, if it really occurs, is a rare
phenomenon.
Bone marrow derived cells (BMDC) & microglia in AD brain
Bone marrow (BM) supplies approximately ten percent of the normal adult
brains microglia, brain immune cells, and this amount increases in the injured
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brain, such as in AD (Bowling et al., 1993, Ip and Yancopoulos, 1994, Hess et
al., 2002, Sanchez-Ramos et al., 2008). In a study by Maler et al. the amount of
hematopoietic stem cells (HSC) in the blood was decreased in AD patients as
compared to age matched controls (Maler et al., 2006). Also there was a
correlation between these low HSC counts and a decrease in cerebral spinal fluid
(CSF) Aβ 1-42 peptide and Aβ ratio 42/40 which have been shown to be possible
CSF markers for AD in patients with mild cognitive impairment (Wiltfang et al.,
2005). Therefore the decrease in HSC may be contributing to the cognitive
deficits seen in AD. Microglia are dysfunctional in their ability to produce the Aβbinding receptor and Aβ-degrading enzymes in the Tg APP/PS1 AD mouse
model (Hickman et al., 2008). Microglia also are attracted to Aβ plaques and can
have both positive and negative effects on the AD brain (Kim et al., 2005, Walker
and Lue, 2005).
The mechanism of microglial accumulation into AD brains is not
completely understood. Circulating leukocytes in the blood express chemokine
receptors such as CC-chemokine receptor 2 (CCR-2). The primary ligand of
CCR-2 is monocyte chemoattractant protein (MCP-1) which mediates the
recruitment of CCR-2 expressing monocytes into the brain as well as activation
of macrophages (Matsushima et al., 1989, Yamamoto et al., 2005). MCP-1
expression occurs mainly on monocytes (Kitagawa et al., 2004). MCP-1 is mostly
expressed in the perivascular space and brain parenchyma during
neuroinflammation (Mastroianni et al., 1998, Losy and Zaremba, 2001, Sindern
et al., 2001, Chen et al., 2003, Sorensen et al., 2004). Other monocyte
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chemotactic pathways that are independent of MCP-1 allow a minimal level of
monocyte attraction under non-disease conditions (Mantovani, 1999). CCR-2 is
expressed in both neurons and astrocytes within the brain, specifically in the
cerebral cortex, the striatum, the limbic system and the cerebellum (Banisadr et
al., 2002, Gillard et al., 2002). CCR-2 is also expressed in microvascular
endothelial cells in both mice and humans (Dzenko et al., 2001).
MCP-1 may also function as a regulator of brain endothelial permeability
in vitro and induce blood-brain barrier (BBB) disruption in vivo (Tekstra et al.,
1999, Stamatovic et al., 2003, Stamatovic et al., 2005). Aβ amyloid peptides can
up-regulate the release of chemokines such as MCP-1 in both monocytes as well
as several cells within the brain (Lue et al., 2001, Dawson et al., 2003). MCP‐1 is
up-regulated early in brains of transgenic mice that develop AD–like pathology
(Ishizuka et al., 1997, Sly et al., 2001, Janelsins et al., 2005, Yamamoto et al.,
2005, El Khoury et al., 2007). Elevated levels of MCP-1 have been observed in
AD patients both in microglia associated with mature senile plaques and in
microvessels isolated from brain cortices (Ishizuka et al., 1997, Grammas and
Ovase, 2001).
Early microglial accumulation is CCR-2 dependent and begins before
formation of AD senile plaques, which suggests that early neurotoxic species of
Aβ are capable of inducing microglial accumulation, probably through the
recruitment of mononuclear phagocytes from the bone marrow and blood (Walsh
et al., 2002, Babcock et al., 2003, El Khoury et al., 2007). The strategy of
blocking the MCP‐1/CCR2 interaction, either genetically or pharmacologically,
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has been proposed as being effective in preventing macrophage‐induced tissue
damage. Loss of MCP-1 function is enough to impair monocyte trafficking in
several inflammatory models (Dawson et al., 2003). Mice bred to have the CCR2 receptor knocked-out (CCR-2-/-) exhibited impairment in modulating
recruitment of monocytes to areas of inflammation (Boring et al., 1997). It also
was reported that cross breeding Tg2576 AD mice with Tg mice deficient in
CCR‐2 (TgCCR‐2‐/‐) resulted in decreased infiltration of microglia, increased βamyloid plaque load and accelerated disease progression (El Khoury et al.,
2007). Antibodies to MCP-1 significantly inhibit the migration of microglia and
monocytes in response to Aβ-stimulated macrophage supernatant in vitro (Meda
et al., 1996, El Khoury et al., 2003).
Hematopoietic growth factors as a treatment for neurogenerative diseases
Hematopoietic cytokines or growth factors (HGF) stimulate cell growth and
differentiation of HSC. Several cytokines known to act as growth factors on the
brain include fibroblast growth factor-2(FGF2), fibroblast growth factor-8
(FGF8),endothelial growth factor (EGF), sonic hedgehog (Shh), bone
morphogenetic protein 4 (BMP4), brain-derived neurotrophic factor (BDNF),
vascular endothelial growth factor (VEGF), stromal cell-derived factor-1 (SDF-1),
stem cell factor (SCF), granulocyte-colony stimulating factor (G-CSF),
granulocyte-macrophage colony stimulating factor (GM-CSF), macrophage
colony stimulating factor (M-CSF), and erythropoietin (EPO). Of these HGF that
act as growth factors on the brain, the following review will focus on those that
have the greatest potential to act as treatments for neurodegenerative diseases,
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including AD, such as SCF, GM-CSF, G-CSF, M-CSF, SDF-1 and EPO. HGF
have several effects on the central nervous system (CNS) (Table 1). They can be
neuroprotective, anti-apoptotic, stimulate stem cell neuronal plasticity, induce the
proliferation and differentiation of NSC into new neurons or glial cells such as
microglia.
Erythropoietin (EPO) is a 30 kDa hematopoietic cytokine consisting of
165 amino acids and is coded by a single copy on chromosome (Maiese et al.,
2004, 2005). The biological activity of EPO appears to be dependent on its
glycosylated chains as well as the disulfide bonds between the cysteine residues
located at 7 and 160 and at 29 and 33 (Chong et al., 2002). EPO is ubiquitous
throughout the body and primarily produced in the kidney through peri-tubular
fibroblasts in the renal cortex (Jacobson et al., 1957, Fliser and Haller, 2007).
The main actions of EPO include to promote red blood cells (RBC) survival
through the prevention of apoptosis in threatened RBC and to stimulate colony
forming erythroid cells to proliferate into new RBC (Lasne and de Ceaurriz, 2000,
Sathyanarayana et al., 2007). The production of EPO has also been indicated to
occur in the liver through Kupffer cells and hepatocytes as well as in the uterus
(Schmeding et al., 2007). Surprisingly EPO production and the presentation of
the erythropoietin receptor (EPOR) have been found to exist in both cells of the
nervous and cardiac/vascular system inferring an extension of its cellular
protective abilities to these systems (Maiese et al., 2004).
Expression of EPO and EPOR have been shown to correlate with
decreased levels of oxygen, or increased metabolic stress, and have been
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shown to be under control of hypoxia-inducible factor 1 (HIF-1). HIF-1 is
constitutively produced in cells, but undergoes elimination through ubiquitination
and proteasome degradation in the presence of oxygen. In hypoxic events,
however, degradation of HIF-1 is inhibited, allowing it to up-regulate the
expression of both EPO and EPOR. The timely appearance of EPO and EPOR in
the event of a decrease in oxygen allows EPO to protect cells from apoptosis
(Maiese et al., 2004, 2005). Currently EPO is used to treat anemia in various
clinical scenarios (Fisher, 2003).
The presence of EPOR on cellular membranes and the synthesis of EPO
have been found to occur in neurons and astrocytes (Marti et al., 1996, Morishita
et al., 1997, Juul et al., 1999a, Brines et al., 2000). EPO is able to cross the BBB
through receptor mediated transport, allowing EPO produced in peripheral
tissues to enter the brain (Brines et al., 2000). This event, however, only
accounts for 6-8% of the total EPO concentration found in the CSF indicating that
most of the EPO in the CSF is produced in the brain (Maiese et al., 2004).
Various regions of the brain have been attributed to production of EPO such as
the hippocampus, cortex, and mid-brain (Maiese et al., 2004, 2005). The
presence of EPO and EPOR are relatively low in the normal brain and only after
metabolic stress or hypoxia does the concentration increase. This has been
indicated by increases in the expression of EPO in the CSF as well as increase
of EPO in postmortem brains that have undergone injury, hemorrhage or stroke
(Juul et al., 1999b, Siren et al., 2001 , Springborg et al., 2003, Sairanen et al.,
2006). EPOR has also been indicated to increase in concentration in chronic
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brain diseases, such as AD, possibly inferring constant hypoxic or metabolic
stress (Assaraf et al., 2007). It is thought that Aβ plaques in the brain, as well as
the characteristic tangle, are strongly correlated to cause of AD (Hardy and
Allsop, 1991, Iwatsubo, 2000). Aβ plaques are believed to increase the amount
of reactive oxygen species in the brain thus increasing the oxidative stress and
Aβ-induced apoptosis associated with AD (Barkats et al., 2000, Sultana et al.,
2004, Boldogh and Kruzel, 2008, Moon et al., 2008).
It has been revealed that EPO is able to attenuate the apoptosis induced
by reactive oxygen species (ROS) which is induced by Aβ. Aβ was shown to
decrease the ratio of Bcl-2/Bax thus leading to the activation of caspase 3 and
eventual apoptosis. However EPO was able to increase this ratio by increasing
the expression of Bcl-2, an anti-apoptotic gene, and by decreasing the
expression of Bax, a pro-apoptotic gene, thus leading to the protection of PC12
cells, a cell line used as a model for neuronal differentiation, from Aβ induced
oxidative stress. This was linked to the activation of the intracellular
Jak2/PI3K/Akt pathways which was indicated by the increase in phosphorylated
Akt when PC12 cells were treated with EPO (Li et al., 2008, Ma et al., 2009). The
fragmentation of DNA through caspases, apoptotic enzymes, is a relatively late
occurring phenomenon as many earlier stimuli also lead to phagocytosis or
apoptosis of cells in the CNS. Aβ plaques are able to induce microglial secretion
of TNF-α as well as other inflammatory cytokines (Bornemann et al., 2001,
Chong et al., 2005a). Also Aβ plaques cause the early expression of externalized
phosphatidyl-serine (PS) signaling microglia to phagocytize the compromised
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neurons (Kang et al., 2003a, 2003b, Chong et al., 2005b). EPO has been shown
to provide long term survival through Akt activation to cause the translocation
and activation of NF-kB to the nucleus leading to expression of anti-apoptotic
genes thus preventing TNF-α induced apoptosis and the activation of caspase
pathways as well as preventing the externalization of PS that would normally
leaded to microglial activation and phagocytosis of a damaged neuron (Wang et
al., 1998, Reed, 2001, Chong et al., 2005c). EPO was indicated to induce the
dephosphorylation and deactivation of GSK-3β by EPO binding its receptor and
up-regulating Akt activity through the Jak2/PI3K pathway thus preventing the
hyperphosphorylation of tau protein and subsequent tangle formation. This
provided a possible avenue in preventing Aβ induced cellular death in the brain
(Sun et al., 2008, Ma et al., 2009). In addition to its neuroprotective abilities, EPO
has the capacity to provide the necessary signaling to cause mesenchymal stem
cells (MSC) to differentiate into neurons during simultaneous hypoxia (Zwezdaryk
et al., 2007, Danielyan et al., 2009). In the presence of EPO, MSC have been
shown to increase the expression of neural markers, such as choline
acetyltransferase (ChAT), neuronal nuclei (NeuN), and muscarinic receptors and
to increase functional markers, such as synaptophysin, alutamate aspartate
transporter (GLAST) and neprilysin (Danielyan et al., 2009). EPO has also been
shown to up-regulate the production of ACh and, along with the increase in
muscarinic receptors, it appears these MSC can be used to replace ACh neurons
that are often associated with cognitive loss in AD (Tsang et al., 2007, Danielyan
et al., 2009). It has also been observed that EPO not only increases the
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differentiation of MSC into neurons, but also inhibits the differentiation into gliallike cells due to the decrease in glial fibrillary acidic protein (GFAP) positive cells
under EPO administration. EPO treated MSC are able to produce glutamine
synthase (GS), which is normally produced by astrocytes to combat glutamate
toxicity, but GS activity is decreased in AD, which causes neurons to synthesize
it (Robinson, 2000, Danielyan et al., 2009). Along with EPO induction of GLAST
and GLT-1 production, it has been suggested that EPO treated MSC can take
over the task of metabolizing glutamate that is normally done by astrocytes (de
Hemptinne et al., 2004, Danielyan et al., 2009). It is therefore hypothesized that
co-administration of transplanted MSC and EPO could offer possible therapeutic
potential in treating AD (Danielyan et al., 2009). Intravenous EPO therapy also
has been shown to have cognitive improvement in other neurocognitive
disorders, such as schizophrenia (Ehrenreich et al., 2007). Although EPO
therapy comes with potential cardiovascular risks due to its potential to increase
blood viscosity as well as blood pressure and therefore EPO derivatives should
be further investigated as a method for AD treatment (Maiese et al., 2009).
Stem Cell Factor (SCF) is an 18.5kDa glycoprotein that acts a HGF and
therefore plays a key role in hematopoiesis. It is also known as c-kit ligand, steel
factor or mast cell growth factor. Its structure is similar to M-CSF. SCF exists in
both a soluble (sSCF) and membrane-bound (mSCF) form. sSCF activates the ckit (SCF) receptor more transiently and the down-regulation is induced more
rapidly than in mSCF. mSCF may help in guiding the HSC to their final
destinations in the body during embryogenesis and be biologically more active
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than sSCF (Broudy, 1997). SCF and its receptor are found in areas throughout
the body, but of particular interest, both are expressed in the CNS, such as in the
neuroproliferative zones in the brain (Matsui et al., 1990, Hirota et al., 1992, Morii
et al., 1992, Hirata et al., 1993).
SCF has several biological functions that have been observed either in
vitro or in vivo. In vitro SCF has been shown to increase the survival of HSC,
generate direct colony-forming cells, to potentiate the ability of epinephrine &
ADP to stimulate platelet aggregation, to assist in serotonin secretion, to promote
melanogenesis and gametogenesis, to have synergistic effects on
megakaryocytes, and to support the growth and function of mast cells (Broudy,
1997). In vivo SCF has been shown to help in stem cell (SC) self-renewal, have a
synergistic effect with other HGF such as G-CSF, have chemotactic effects for
SC, to assist in the development of early T cells, and to help in the mobilization of
HSC from the bone marrow into the blood (Broudy, 1997). Its specific functions in
the CNS include acting as a survival factor and chemokine for NSC,
neurogenesis, neuroprotective effects, and modulation of microglia (Zhang and
Fedoroff, 1999, Jin et al., 2002, Erlandsson et al., 2004, Dhandapani et al.,
2005). SCF also has an increased expression in the injured brain, mobilization of
BMSC into the brain through systemic administration of SCF in the normal brain
and mobilization of neuron-like BMSC & resident brain NSC to areas of brain
injury such as areas of ischemia (Corti et al., 2002, Sun et al., 2004, Kawada et
al., 2006, Zhao et al., 2007). SCF is primarily produced by neurons not the glial
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cells in the brain, as intense staining for SCF can be observed in the neutropil
(Sun et al., 2004).
It has been shown by Leyhe et al. that current AD treatments such as
donepezil (AChE-I) may not only act by increasing synaptic connectivity through
the increase of ACh, but also through the increase of HGF, such as BDNF and
SCF (Leyhe et al., 2009). Those AD patients with higher levels of SCF had a
higher level of cognitive function, or a smaller decrease in loss of cognitive
function, than those with lower levels of SCF (Leyhe et al., 2009). AChE-I may be
acting by activating protein kinase C (PKC) which cleaves mSCF releasing it
from the cell surface. This increase in SCF may be responsible for the increase
of BDNF and decrease in neuroinflammation through the suppression of
microglia (Zhang and Fedoroff, 1998).
In c-kit mutant rats a decrease in escape latency with repeated trials of the
water maze was not shown as in the wild type, which displayed impairment in
spatial memory. These c-kit mutant rats also showed impairment in hippocampal
synaptic potentiation in comparison to wild type rats in studies with paired-pulse
facilitation (PPF) in the mossy fiber-CA3 (cornu ammonis 3) hippocampal
pathway and long term potentiation (LTP) (Katafuchi et al., 2000). Therefore a
lack of SCF impairs both spatial memory and hippocampal synaptic potentiation
or long term memory.
Lower levels of SCF have been observed in plasma levels of AD patients
in comparison to age matched healthy controls. Also lower levels of plasma SCF
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have been significantly correlated to an increase in the severity of dementia.
Patients with AD in comparison to those with non-inflammatory neurological
disease (NIND) had significantly lower CSF levels of SCF. No correlation exists
between the levels of SCF found in the CSF versus the plasma, so the SCF in
these different locations may have different sources (Katafuchi et al., 2000).
Therefore, a decrease in HGF, such as SCF, could be contributing to a decrease
in HSC in patients with AD. Although due to the negative feedback loop between
sSCF and mSCF it is possible sSCF is decreasing while mSCF is increasing
(Miyazawa et al., 1995).
Both the HGF SCF and FGF2 protein and mRNA levels are increased with
hypoxia in cell culture. Also SCF is increased in immature neurons in both SGZ
and SVZ in the rat brain and administration of SCF increases bromodeoxyuridine
(BrdU) labeling of immature neurons, showing the effect of SCF on areas of
neurogenesis (Jin et al., 2002). In those cells adjacent to the areas of brain injury
higher levels of SCF are expressed then those that are a further distance from
the injury and SCF mRNA is over-expressed in the injured area of the brain (Sun
et al., 2004).
In subacute brain ischemia the administration of SCF plus G-CSF
decreased the infarction size and resulted in functional improvement (Kawada et
al., 2006). In a study by Piao et al. SCF plus G-CSF treatment in mice with a
model of chronic stroke increased BMSC mobilization and differentiation resulting
in an increase in neurogenesis and angiogenesis and therefore enhancement of
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brain repair in ischemia (Piao et al., 2009). Both SCF and G-CSF pass through
the intact BBB (Zhao et al., 2007).
Although SCF may be a potential treatment for neurological diseases,
such as AD and stroke, it has also been shown to have side effects in early
clinical trials. At sites of injection it can cause wheals due to activation of mast
cells and darkening in pigmentation due to activation of melanocytes, although if
given at lower doses in conjunction with a synergistic factor such as G-CSF
these side effects may be eliminated (Broudy, 1997). Phase 1 clinical trials have
been completed in use of SCF as a treatment for aplastic anemia,
myelodysplasia and AIDS/AIDS-related malignancies.
Granulocyte Macrophage-Colony Stimulating Factor (GM-CSF) is a 23
kDa glycoprotein with a four helical bundle structure (Nicola, 2001a). It is a HGF
that assists in the maturation and differentiation of HSC into the lineage of the
granulocytes & macrophages. HGF, such as GM-CSF, stimulate the progression
of the cell cycle through the up-regulation of cyclins and therefore stimulate the
proliferation of microglia and their transformation into the ameboid (active) form
(Koguchi et al., 2003). According to Malipiero et al. GM-CSF is made from
astrocytes in the brain, although in a more recent study by Schabitz et al. GMCSF is found in similar cells in the brain as its receptor, therefore predominantly
in neurons and to a lesser extent in oligodendrocytes (Malipiero et al., 1990,
Schabitz et al., 2008).
Its receptor (GM-CSFR) is heterodimeric and it contains an α chain, the
GM-CSF ligand binder, and a β chain, the signal transducer which is coupled to
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STAT pathway (Nicola, 2001b, Maurer et al., 2008). GM-CSFR is found both on
hematopoietic cells as well as in the CNS (Sawada et al., 1993). In neurons in
the uninjured brain the GM-CSFR is found throughout the brain in areas such as
hippocampus CA2 and CA3, entorhinal cortex, pyramidal cells in cortex, as well
as several other areas. Also GM-CSFR can be detected in some
oligodendrocytes, but not microglia or astrocytes (Schabitz et al., 2008). But
according to Guillemin et al. GM-CSFR can be found on astrocytes (Guillemin et
al., 1996). GM-CSFR has been found on NSC stained with nestin in the
hippocampus (Kruger et al., 2007). In areas of the brain with ischemia and the
penumbra, an area where neurons are at risk of dying due to nearby infarct, upregulation of the receptor in large pyramidal neurons may be an adaptive
response to the neuronal damage (Schabitz et al., 2008).
In the peripheral nervous system GM-CSF stimulates phagocytosis of
myelin during wallerian degeneration (WD), although it is inhibited in a later stage
of WD by a binding protein (Reichert et al., 1994, Mirski et al., 2003). In the CNS
GM-CSF causes proliferation, induction and differentiation of microglia and has a
strong anti-apoptotic effect on recruited neutrophils and neurons (Suzumura et
al., 1996, Coxon et al., 1999, Schermer and Humpel, 2002, Schabitz et al.,
2008). GM-CSF asserts this anti-apoptotic effect through increase in the antiapoptotic proteins Bcl-Xl and Bcl-2 and partially through activation of the Akt
pathway; this anti-apoptotic effect can be activated by such stimuli as ischemic
insult. GM-CSF has been identified as a neuronal growth factor in the brain which
is both anti-apoptotic and diminishes infraction size in vivo in rats (Schabitz et al.,
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2008). GM- CSF treatment in a disease model of spinal contusion decreased
apoptosis within the spinal cord (Ha et al., 2005). NSC treated with GM-CSF in
vitro had a significant increase in staining for β III-tubulin and MAP-2 or an
increase in differentiation of NSC into neurons (Kruger et al., 2007).
In a study by Manczak et al. AD transgenic (Tg) 2576 mice were treated
with anti-GM-CSF antibody and a significant decrease was seen in Aβ plaque
deposits, soluble Aβ 1-42 production, and microglial activation (Manczak et al.,
2009). When levels of cytokines, such as GM-CSF, are decreased the level of
microglia also decreased, therefore elevated GM-CSF levels in AD may
contribute to the increase of microglia in the brain (Tarkowski et al., 2001).
Administration of GM-CSF and Aβ through adenovirus vectors intranasally in
Tg2576 mice resulted in lower Aβ levels in the brain in comparison to control
(Kim et al., 2004). In Tg APP mice treated with a combination of Aβ/GMCSF/Interleukin-4 (IL-4) antibodies significantly decreased the Aβ plaque load
(DaSilva et al., 2006).
An increase in GM-CSF levels have been observed in the CSF and
plasma in patients with stroke, AD, and vascular dementia, although patients with
stroke only had an elevation of GM-CSF in CSF. Elevation in GM-CSF may be
due to an increase in neuronal damage and cell death, as a positive correlation
was shown between GM-CSF and markers for neuronal damage, such as Tau
and Fas/APO-1 gene, (Tarkowski et al., 1997, Tarkowski et al., 2001, Tarkowski
et al., 2003). In an observational study both GM-CSF and G-CSF were
overproduced by AD-derived peripheral blood mononuclear cells (PBMC)
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activated by recombinant Aβ 1-42 (Pellicano et al., 2010). In another study, MCSF, G-CSF or GM-CSF was administered unilaterally into the hippocampi of
aged cognitively impaired AD mice via 5 μg bolus injections G-CSF and GM-CSF
both significantly reduced amyloidosis throughout the treated brain hemisphere
one week following bolus administration, although there was a greater reduction
of amyloid with GM-CSF treatment. Subcutaneous GM-CSF (5 μg daily injections
x 20) administration in AD mice significantly reduced brain amyloidosis and
reversed the cognitive impairment, while increasing hippocampal synaptic area
and microglial density (Boyd et al., 2010).
Clinically GM-CSF, or Leukine a recombinant human GM-CSF, has been
used for the treatment of neutropenia. GM-CSF, as well as G-CSF, is in clinical
trials for use as a treatment for stroke and AD. And therefore may possess the
potential to be a future treatment for neurodegenerative diseases like AD.
Macrophage-Colony Stimulating Factor (M-CSF) (aka CSF-1) is
another HGF that is 80-100 kDa glycoprotein or 130-160 kDa chondroitin sulfatecontaining proteoglycan, or expressed as membrane bound 68-86 kDa
glycoprotein on M-CSF producing cells. In all its active forms it is dimeric
(Stanley et al., 1994). M-CSF is produced by astrocytes (Giulian and Ingeman,
1988). M-CSF has also been shown to reduce cognitive deficiency and Aβ
plaque load in APP/PS1 Tg mice, receiving M-CSF treatment intraperitoneally
(ip). This was observed by decreased escape latencies in repeated T-water
maze trials in M-CSF treated Tg mice and wild type mice versus saline-treated
Tg mice which shows an improvement in spatial memory with M-CSF treatment.
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M-CSF treated 6mo old Tg mice had an improved quality of nest building which
reflects diminished social withdrawal and apathy as compared to saline-treated
Tg mice. Also M-CSF treated Tg mice had a higher ratio of microglia per plaque
than saline-treated Tg. Although the increase in microglia per plaque could
potentially be related to the decreased density, size, and overall Aβ burden in the
plaques seen in the M-CSF treated Tg mice (Boissonneault et al., 2009). It has
also been shown that M-CSF can promote the proliferation, activation and
development of microglia; and therefore mice with decreased levels of M-CSF
have a lower amount of microglia found in the brain (Giulian and Ingeman, 1988,
Raivich et al., 1994, Davoust et al., 2006). M-CSF causes proliferation of
microglia in culture without affecting its response to lipopolysaccharide (LPS) or
Aβ, therefore M-CSF increases amount of microglia without affecting microglial
activation responses (Vidyadaran et al., 2009). Low levels of M-CSF in presymptomatic AD in combination with low levels of other HGF displays a
progression towards a decline of cognitive function to dementia (Ray et al.,
2007).
In a study by Laske et al., 50 patients with AD had significantly increased
M-CSF plasma levels in comparison to 22 patients with mild cognitive impairment
(MCI) and 35 age-matched healthy controls. In contrast, MCI patients showed
significantly decreased M-CSF levels in CSF compared to AD patients and 20
patients with other non-inflammatory neurological disease (NIND). M-CSF, but
not Aβ 1-42 and tau-protein, was a significant parameter for distinction between
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MCI and NIND patients. This supports that M-CSF in CSF could be a putative
biomarker for MCI (Laske et al., 2010).
Stromal cell-derived factor-1(SDF-1), also known as Chemokine (C-X-C
motif) ligand 2 (CXCL2), is a member of the C-X-C subfamily of chemokines and
therefore is a potent chemoattractant for HSC that are expressed in the BM
(Bleul et al., 1996, Aiuti et al., 1997, Lapidot et al., 2005, Zhou et al., 2007).
CXCL2 and its receptor CXCR4 may play a role in blood vessel growth and
development as well as attraction of HSC to injured vessel walls (Carr et al.,
2006, Langer et al., 2006, Stellos et al., 2008). It plays an important role in the
mobilization, differentiation and adhesion of HSC and has neuroprotective effects
in the CNS (Robin et al., 2006, Stumm and Hollt, 2007, Stellos et al., 2008).
Decreased plasma levels of SDF-1 have been seen in patients with AD (Laske et
al., 2008). Therefore low levels of SDF-1 may further contribute to the deficient
HSC support in the AD brain.
In a study by Stellos et al., peripheral blood concentrations of circulating
CD34+/CD133+ and CD34+ progenitor cells were measured in 45 AD patients
and in 30 healthy elderly controls by flow cytometry. AD patients with moderate
to severe dementia showed significantly increased circulating CD34+/CD133+
and CD34+ progenitor cells compared to healthy elderly controls independent of
cardiovascular risk factors and medication. In addition, the number of circulating
CD34+/CD133+ progenitor cells in AD patients was significantly inversely
correlated with cognitive function, age, and plasma levels of SDF-1, a potent
chemokine for progenitor cells (Stellos et al., 2010) .
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In another study, memory deficits in an AD mouse model were
significantly improved by intraperitoneal injection of G-CSF/AMD3100 (CXCR4
antagonist) and simultaneous intracerebral injection with SDF-1α (to help induce
migration of BM-HPC into the brain), but Aβ deposition was unchanged (Shin et
al., 2011). Microglial activation was increased with alternative activation of
microglia to a neuroprotective phenotype. Also by utilizing an amyloid precursor
protein/presenilin 1 (APP/PS1)-green fluorescent protein (GFP) chimeric mouse,
BM-derived GFP positive microglia were identified in the brain. Additionally,
increased hippocampal neurogenesis and improved memory was observed in
mice receiving combined G-CSF/AMD3100 and SDF-1α treatment, but not in
controls or in animals receiving each treatment alone. These results suggest that
SDF-1α is an effective adjuvant in inducing migration into brain of the
endogenous BM-HPC, mobilized by G-CSF/AMD3100, and that the two can act
synergistically to produce a therapeutic effect. This approach also shows
potential as a therapeutic option for the treatment of AD patients in the future
(Shin et al., 2011).
Of greatest importance to our laboratory, granulocyte colony
stimulating factor (G-CSF) is a 19 kDa glycoprotein formed into 4 antiparallel
alpha helices (Wells and de Vos, 1996). G-CSF is a HGF that stimulates the
proliferation and differentiation of HSC and exists in both a 174 and a 180 amino
acid forms, although the 174 form is more abundant and active and has been
used in three proprietary recombinant G-CSF proteins including lenograstim
(Granulocyte®), filgrastim (Neupogen®), and pegylated filgrastim (Neulasta®)
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which has a longer duration of action (Sanchez-Ramos et al., 2008). G-CSF has
been shown to be synthesized by many cell types including bone marrow stromal
cells, fibroblasts, and macrophages (Malipiero et al., 1990, Demetri and Griffin,
1991, Wells and de Vos, 1996) and its receptor G-CSFR has also been indicated
to be just as ubiquitous as it can be found on the cell surfaces of endothelial
cells, lymphocytes, platelets, and neutrophils (Bussolino et al., 1989, Hanazono
et al., 1990, Shimoda et al., 1993, Morikawa et al., 2002). G-CSF and G-CSFR
are also both expressed by neurons in several areas of the brain including
pyramidal cells in cortical layers (specifically II and V), Purkinje cells of the
cerebellum, SVZ, and in cerebellar nuclei in rats (Schneider et al., 2005). Also
the G-CSF ligand has been identified in cells within the CA3 region of the HC,
SGZ and the hilus of the DG, entorhinal cortex, and the olfactory bulb (Schneider
et al., 2005). In postmortem studies G-CSFR has been found in the human
frontal cortex (Schneider et al., 2005).
G-CSFR is composed of six functional domains which are broken up into
an immunoglobulin-like domain, a cytokine receptor-homologous domain (CRH)
and three additional fibronectin type III domains within its extracellular region. By
G-CSF binding to G-CSFR various signaling cascades can be ignited. G-CSF
induces the Janus kinase (JAK)/ signal transducer and activator transcription
(STAT) pathway, the Ras/Mitogen activated protein (MAP) kinase, and
Phosphatidyl inositol 3-kinase (PI3K)/ protein kinase B (aka Akt) pathways.
These various pathways have been shown to induce cellular proliferation,
apoptotic processes, and anti-inflammatory processes (Tian et al., 1994,
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Shimoda et al., 1997, Hunter and Avalos, 1998, Dong and Larner, 2000, Ward et
al., 2000). These signaling pathways induced by G-CSF are a major objective of
current studies (Sampson et al., 2007).
In a rat stroke model G-CSF and G-CSFR are up-regulated two hours
post-occlusion and reperfusion of the middle cerebral artery (MCA) in the
ipsilateral forebrain (Schneider et al., 2005). In another study looking at ischemia,
G-CSF mRNA levels were greatly elevated in the ischemic brain versus the
normal brain although returned to normal after two days. This elevation in G-CSF
mRNA extended to non-ischemic areas of the frontal cortex after
photothrombosis in a rat model of focal cerebral ischemia (Kleinschnitz et al.,
2004). G-CSF in combination with SCF administered 10 days after ischemia
resulted in improved motor performance, induced transition of BM-derived
neuronal cells into the penumbra, and stimulated proliferation of brain-derived
NSC in the zones of neuroproliferation (Kawada et al., 2006). G-CSF may have a
protective autocrine signaling mechanism, similar to that seen in other HGF like
EPO in response to brain injury (Solaroglu et al., 2007). It is known that G-CSF is
able to mobilize CD34+ HSC from the BM into the blood allowing them to
circulate and migrate to areas of ischemic damage (Bodine et al., 1994, Grigg et
al., 1995, Orlic et al., 2001a, Orlic et al., 2001b, Shyu et al., 2004).
In a study by Tsai et al. two AD models were used to evaluate the effect of
G-CSF on AD mice (Tsai et al., 2007). In the acute model aggregated Aβ was
injected into the hippocampal-cortical junction of the mouse brain and the chronic
model used the Tg2576 AD mouse. After a 5 day dosing of G-CSF in the acute
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AD mice learning and memory function in the Morris water maze was restored to
levels similar to that of the control mice. It was found that white blood cell levels
were elevated in the G-CSF treated mice. BrdU+/NeuN double-labeling of cells
was increased in both the acute and chronic AD mice models treated with GCSF, although this double-labeling was not necessarily found in the neurogenic
niches therefore may not be a result of improved neurogenesis, but of cellular
repair or death. 20% of the BrdU+ cells in the acute AD mice were CD34+ which
could indicate that HSC were mobilized by G-CSF and directed to the Aβ
injection site in the brain. After a 5 day dosing of G-CSF Tg2576 mice an
improvement in memory and learning was seen due to the reduced latency in the
Morris water maze similar to the improvement seen in the acute AD mice treated
with G-CSF. Three months after treatment with G-CSF Tg2576 mice were
retested and found to still have significant learning and memory abilities over the
untreated mice indicating a long lasting effect of G-CSF. The amount of
acetylcholine (ACh) was increased by 20% in G-CSF treated Tg2576 mice,
showing a potential improvement in synaptic potential. Although learning and
memory were improved no reduction in the Aβ plaques were seen. Therefore,
overall the treatment with G-CSF in both the acute and chronic mouse model for
AD showed an induction in the release of HSC from the bone marrow, potential
stimulation of neurogenesis, an increase in ACh production and an overall
improvement in neurological function, specifically improvement in learning and
memory (Tsai et al., 2007).
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In a study previously done in this laboratory Tg APP/PS1 AD mice were
treated with s.c. G-CSF injections every other day for two weeks (SanchezRamos et al., 2009). A reduction in Aβ deposits in both the hippocampus and
entorhinal cortex was seen as well as a reduction in soluble Aβ within the
hippocampus, which differs from what was seen in the study done by Tsai et al
(Tsai et al., 2007). A correlation was observed between a decrease in Aβ
deposition and improvement in cognitive function. In other studies it has been
shown that an increase in Aβ decreases cognitive function (Arendash et al.,
2001, Ethell et al., 2006). Improved cognitive function also was seen with the
removal of Aβ in the case of long term caffeine administration (Arendash et al.,
2006) and in the case of administration of Leuprolide acetate (a gonadotropin
releasing hormone (GRH) analogue) (Casadesus et al., 2006). It was proposed
that G-CSF reduces the deposited Aβ, which then causes the soluble Aβ to
become deposited and then it to be removed by G-CSF induced pathways. This
mechanism could prove to be important as the soluble form of Aβ has been
indicated to be more toxic than the deposited form of Aβ and can also inhibit LTP
(Walsh et al., 2002, Walsh and Selkoe, 2004). Despite the increase in neutrophil
count with G-CSF treatment due to its neuroprotective effects the release of proinflammatory mediators is inhibited (Hartung, 1998, Boneberg et al., 2000). In GCSF treated APP/PS1 mice synaptophysin density also was increased in the
hippocampus indicating an increase in synapses. Increased levels of Aβ have
been linked to decreased levels of synapses, but with decreased levels of Aβ the
loss of synapses is self-correcting leading to an improvement in LTP (Hsia et al.,
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1999, Mucke et al., 2000 , Lombardo et al., 2003, Oddo et al., 2003). G-CSF was
also shown to increase neurogenesis, but it is unclear whether or not
neurogenesis is directly influential on the cognitive improvement of Tg AD mice
(Kuhn et al., 2007).
In a previous study done by Laske et al. a significant decrease G-CSF
plasma levels in patients with early AD was seen in comparison to healthy age
matched controls (Laske et al., 2009). Also a significant inverse correlation was
shown between G-CSF plasma levels and Aβ 1-42 levels in the CSF in AD
patients. A significant inverse correlation in G-CSF levels and age was seen in
both AD patients and healthy controls, therefore G-CSF levels decrease with
age, it also would be interesting to assess if G-CSF levels decreased as the
severity of AD progresses, although unfortunately it was not assessed in this
study. The decrease in G-CSF in early AD may contribute to the deficient HSC
support in the AD brain (Laske et al., 2009).
Currently G-CSF is being used therapeutically to induce proliferation of
neutrophils in patients suffering from neutropenia after anti-cancer drug therapy
as well as in patients with congenital neutropenia (Welte et al., 1996,
Kocherlakota and La Gamma, 1997, Carlsson et al., 2004). Because G-CSF is
already in clinical use, it has been suggested that it could be used to treat various
neurological disorder without compromising the patient. Clinical trials to examine
the ability of G-CSF to treat ischemic strokes are currently being assessed
(Schabitz and Schneider, 2007). Additionally G-CSF has been used to treat
myocardial infarctions (Takano et al., 2003, Kuethe et al., 2004, Nienaber et al.,
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2006, Ripa et al., 2006, Suzuki et al., 2006). Due to the AD brain lack of
hematopoietic support it could be promising to further evaluate HGF such as GCSF as potential treatments for AD.
Specific Aims
G-CSF, known generically as filgrastim, has been reported to have
disease-modifying effects in a transgenic mouse model of AD. G-CSF is known
to stimulate hematopoieis in bone marrow, and to increase circulating levels of
stem/progenitor cells and neutrophils. G-CSF also has direct actions on CNS
neural cells and may rescue dying or dysfunctional neurons and promote
hippocampal neurogenesis. The overall objective of this dissertation is to
determine the extent to which the actions of G-CSF on blood stem/progenitor
cells and inflammatory cells are responsible for its disease-modifying effects in
AD in comparison to direct actions on CNS neurons.
Specific Aim 1. To test the hypothesis that G-CSF promotes trafficking of
blood stem/progenitor cells from marrow to blood and from blood to brain where
marrow-derived monocytes (or pro-monocytes) differentiate into fresh microglia,
a set of in vitro and in vivo experiments will be conducted. In the in vitro studies,
various parameters will be assessed including binding kinetics, anti-apoptotic
proteins, proliferation, viability, adhesion, and migration in order to further
describe the mechanism of action of G-CSF on marrow-derived monocytes. For
the in vivo studies, a chimeric AD mouse model with green fluorescent bone
marrow cells will be treated with G-CSF in order to determine the proportion of
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total microglia that derive from the periphery (GFP+ cells). Secondary endpoints
in the in vivo studies will be total amyloid burden and microgliosis in the
hippocampus and entorhinal cortex.
Specific Aim 2. To test the hypothesis that MCP-1 mediates the
mobilization of BMDC triggered by G-CSF administration, in vitro experiments will
be conducted. Using a cell migration system, the effects of an antagonist of the
MCP-1 receptor expressed on monocytes (also known as the CCR-2 receptor)
on monocyte migration will be evaluated. In addition, the effects of G-CSF, with
and without the CCR-2 receptor antagonist on monocyte migration will be
assessed.
Specific Aim 3. To test the hypothesis that G-CSF has direct actions on
hippocampal neurons and may promote neurogenesis, thereby ameliorating or
mitigating the behavioral deficits observed in Tg AD mice as they age; both in
vitro and in vivo experiments will be utilized. In the in vitro studies, various
parameters will be assessed including binding kinetics, anti-apoptotic proteins,
proliferation, and viability in order to further describe the mechanism of action of
G-CSF on CNS neurons. For the in vivo studies, an AD mouse model will be
treated with G-CSF in order to determine the effect of G-CSF on hippocampal
neurogenesis through analysis of incorporation of BrdU in the SGZ of the HC and
immature neuronal markers. Secondary endpoints in the in vivo studies will be
total amyloid burden and microgliosis in the hippocampus and entorhinal cortex.
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Successful completion of this study will increase understanding of the
primary mechanism(s) responsible for the beneficial effects of G‐CSF on the AD
disease process, which may result in new therapeutic targets for the treatment of
AD.
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Table 1. Summary of effects of hematopoietic growth factors (HGFs) in brain.
SCF

M-CSF

Survival factor &
chemokine of NSCs

Reduced
cognitive
deficiency and Aβ
plaque load in
APP/PS1 Tg
mice

GM-CSF

SDF-1

G-CSF

G-CSF +SCF

Upregulation of its
receptor in areas of
ischemia in the brain

Plays role in
angiogenesis &
attraction of HSCs to
injured vessel walls

Upregulated in
ischemic brain

Neurogenesis

Decreased Aβ
plaque deposition
in AD mice

Receptor found on
NSC in hippocampus

Potent
chemoattractant for
HSCs

Neurogenesis in
AD mice

Increased levels of it
and its receptor in the
brain with hypoxia or
ischemia

Neuroprotective
effects

Improvement in
spatial memory in
AD Tg mice

Anti-apoptotic effect
on neurons & effect
induced by ischemia

Neuroprotective
effects

Protective
autocrine signaling
in response to
brain injury

Anti-apoptotic effects for
NSCs against Aβ
induced oxidative stress

Modulation of
microglia &
possible
suppression of
microglia to
decrease
neuroinflammation

Promotion of the
proliferation,
activation and
development of
microglia

Decreased size of
infarct in ischemia &
decreased apoptosis
in spinal cord with
spinal contusion

Decreased plasma
levels in AD pts

Improvement in
learning, cognitive
function and
memory in AD
mice

Prevention of
hyperphosphorylation of
tau and formation of
neurofibrillary tangles

Mobilization of
BMSC into the
brain

Low levels in presymptomatic AD
in combination
with low levels of
other HGFs
displays a
progression
towards a
decrease of
cognitive function
to dementia

Proliferation &
differentiation of
microglia

Reduction of Aβ
plaques in
hippocampus &
entorhinal cortex
as well as
decreased soluble
Aβ in the
hippocampus

Expression of antiapoptotic genes
preventing the activation
of caspases and
microglia as well as
prevention of
phagocytosis of
damaged neurons

In brain primarily
produced by
neurons

In brain primarily
produced by
astrocytes

In brain primarily
produced by
astrocytes or
neurons (conflicting
data)

Mobilization of BMderived microglia to
Aβ plaque in AD
mice

In brain produced in
neurons & astrocytes

Mobilization of
neuron-like BMSC
& resident brain
NSC to areas of
brain injury such as
ischemia

Antibodies to GMCSF causes
decreased Aβ
plaque deposits,
decreased soluble
Aβ 1-42 production,
and microglial
activation in AD pts

Increased
synaptophysin in
AD mice

Increased differentiation
of MSCs to neurons and
decreased differentiation
to glial-like cells in the
presence of hypoxia

AChE-I increases
SCF in AD pts

Combination of
Aβ/GM-CSF/IL-4
antibodies
decreased Aβ
plaque load

Plasma levels
decreased in AD
pts

Upregulation of ACh
and muscarinic
receptors

Increased SCF
levels is correlated
with increased
cognitive function in
AD pts

GM-CSF
administered in
combination with Aβ
through adenovirus
vectors intranasally
in AD mice resulted
in lower Aβ levels in
the brain

As plasma levels
decrease, Aβ1-42
levels increase in
the CSF in AD
patients

Increased production of
glutamine synthase in
neuronal-like cells

Improved
neurogenesis,
angiogenesis, &
enhancement of
brain repair in
ischemia

EPO
Its receptor is found in
both the nervous &
cardiovascular system

May increase
BDNF
Modulate spatial
memory and
hippocampal
synaptic
potentiation
Increased levels in
areas of brain injury
Lower plasma
levels of SCF in AD
pts
NSCs, neural stem cells; BMSCs, bone marrow stem cells; AChE-I, acetylcholinesterase inhibitors; SCF, stem cell factor; AD, Alzheimer’s disease; BDNF, brainderived
neurotrophic factor; CSF, cerebrospinal fluid; MSCs, mesenchymal stem cells.
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Figure 1. Granulocyte colony-stimulating factor (G-CSF) has direct actions on bone marrow
hematopoietic stem cells (HSCs), as well as direct and indirect effects on brain.
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Chapter 2: Comparison of the Cellular Effects of G-CSF on Neurons and
Monocytes
Abstract
An expanding body of animal and human research attests to the
neurotrophic potential of granulocyte colony stimulating factor (G-CSF) in the
treatment of stroke and neurodegenerative diseases. G-CSF has been reported
to improve hippocampal-dependent learning, increase microgliosis, decrease
amyloid burden and stimulate hippocampal neurogenesis in a mouse model of
AD. The objective of the present study was to elucidate differences and
similarities between brain cells and bone marrow-derived cells exposed directly
to G-CSF. Method: Cell culture models of monocytes (THP-1) and neurons (SHSY5Y) were incubated with G-CSF. The following parameters were measured:
G-CSF receptor binding kinetics using [125I]-G-CSF; DNA synthesis using [3H]thymidine incorporation; viability using a live-dead assay; signal transduction, in
particular expression of alternatively spliced protein kinase C (PKCδVIII) and
anti-apoptotic protein Bcl2; changes in adhesiveness and migratory properties
induced by G-CSF in the monocytes. Results: G-CSF receptor binding kinetics in
neurons differed from that in monocytes, with Kd in neurons being significantly
higher than that of monocytes. Addition of G-CSF to THP-1 cells and to SHSY5Y resulted in a concentration-dependent increase in DNA synthesis that was
similar in both cell lines. Despite higher affinity of G-CSF for receptors on
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monocytes, G-CSF treatment increased Bcl2 expression in neurons at lower
concentrations than that required in monocytes. G-CSF treatment improved
viability in neurons, but not in monocytes. G-CSF did not increase either cellular
adhesiveness or migration through a semi-permeable membrane, whereas
monocyte chemotactic protein (MCP-1) significantly improved migration.
Conclusions: The cellular and molecular responses to G-CSF treatment of
monocytes suggest that neither changes in adhesiveness nor migratory capacity
are responsible for the beneficial effects of G-CSF administration in a Tg mouse
model of AD. It is likely that the increased microgliosis observed in Tg AD mice
treated with G-CSF is a consequence of increased levels of circulating
monocytes in the setting of Aβ-fueled neuroinflammation and MCP-1 release
which facilitates monocyte infiltration.
Introduction
G‐CSF (granulocyte colony stimulating factor or Filgrastim) is a
therapeutic hematopoietic cytokine commonly used for treatment of neutropenia
and to increase generation of hematopoietic stem/progenitor cells in bone
marrow donors (Dale, 2003, Pusic and DiPersio, 2008). G‐CSF is naturally
synthesized by several cell types including endothelium, macrophages, bone
marrow stromal cells, fibroblasts and a number of other immune cells (Malipiero
et al., 1990, Demetri and Griffin, 1991, Wells and de Vos, 1996). Interestingly, GCSF also exerts neurotrophic effects and has been identified, along with its
receptor (G-CSFR), in neurogenic zones of the hippocampus (HC), the subventricular zone and the olfactory bulb (Schneider et al., 2005). G-CSF and G-
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CSFR are also both expressed by neurons in several other areas of the brain
including pyramidal cells in cortical layers (specifically II and V), entorhinal
cortex, Purkinje cells of the cerebellum, and in cerebellar nuclei in rats
(Schneider et al., 2005). The G-CSF receptor is also fairly ubiquitous and can be
found on the cell surfaces of endothelial cells, lymphocytes, platelets, and
neutrophils (Bussolino et al., 1989, Hanazono et al., 1990, Shimoda et al., 1993,
Morikawa et al., 2002).
Mice bred to have a deficiency in G-CSF exhibited defects in memory
formation and the development of motor skills, as well as impairment in the
induction of long term potentiation in the CA1 region, decrease in neuronal
precursor cells in the dentate gyrus (DG) and decreased dendritic complexity in
neurons in the DG and CA1 region of the HC (Diederich et al., 2009b). The
defects seen in G-CSF deficient mice support the importance of G-CSF as an
essential neurotrophic factor and its part in facilitating neural cells in hippocampal
formation (Diederich et al., 2009b). In combination with cognitive training, G-CSF
can also significantly improve spatial learning and new neuron survival in the
hippocampus (Diederich et al., 2009a).
A significant decrease of G-CSF plasma levels was found in patients with
early AD in comparison to healthy age matched controls (Laske et al., 2009). In
addition, the authors reported a significant inverse correlation between G-CSF
plasma levels and Aβ1-42 levels in the cerebrospinal fluid of AD patients. These
observations, coupled with evidence that bone marrow-derived cells contribute to
microgliosis in AD, led to studies of the disease-modifying impact of G-CSF in
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animal models of AD(Malm et al., 2005, Tsai et al., 2007, Sanchez-Ramos et al.,
2009).
Treatment of transgenic (Tg) APP/PS1 AD mice with subcutaneous GCSF for two weeks resulted in significant reduction of total β-amyloid (A-β)
deposits in both hippocampus (HC) and entorhinal cortex (EC) (Sanchez-Ramos
et al., 2009). G-CSF treated Tg mice also exhibited a significant increase in
microgliosis in both HC and the EC. A correlation was observed between
decreased Aβ deposition and improvement in cognitive function as well as a
suggestion of increased neurogenesis (Sanchez-Ramos et al., 2009). The
mechanism of action of G-CSF responsible for the cognitive changes
(performance in the radial arm water maze) in Tg mice is unknown. However, it is
clear that G-CSF has the ability to act on cells in the peripheral immune system,
such as on hematopoietic stem progenitor cells and monocytes (Kondo et al.,
1991), as well directly upon CNS neurons (Schneider et al., 2005). It is not easy
in animal studies to determine the extent to which the disease-modifying and
beneficial effects on behavior are mediated by stimulation of hematopoiesis, with
increased numbers of circulating monocytes and increased infiltration of these
cells into brain, and/or from the direct actions of G-CSF on neurons and neural
stem/progenitor cells in hippocampus.
The objective of the present study was to elucidate differences and
similarities between brain cells and bone marrow-derived cells exposed directly
to G-CSF. Understanding the molecular and cellular responses triggered by GCSF will provide insights into the complex mechanisms of action of G-CSF
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administered in vivo. A series of experiments were undertaken to compare
effects of G-CSF on monocytes and neurons in cell culture models. The
parameters of cellular functions compared were a) G-CSF receptor binding
kinetics, b) DNA synthesis, c) viability assay and d) signal transduction, in
particular expression of alternatively spliced protein kinase C (PKC) and the antiapoptotic protein Bcl2. Finally, migration and adhesiveness of monocytes were
investigated in vitro to determine if these actions play a role in mobilization and
infiltration of circulating monocytes into brain.
Materials & Methods
Cells and cell lines. Two cell lines have been chosen for the in vitro
studies. One is a human monocyte cell line that is representative of the
peripheral immune system, THP-1, which grows in suspension. THP-1 cells are
derived from a human acute monocytic leukemia cell line often used as a model
for human blood monocytes, but it is important to recognize that they are not fully
differentiated monocytes, but promonocytes (Auwerx, 1991, Tompa et al., 2011).
The other cell line is a human neuroblastoma cell line SH-SY5Y, which is a
mixed cell line although only adherent cells were utilized (Xie et al., 2010). Both
cell lines are known to express the G-CSFR and the THP-1 cell line is also
known to express the receptor, CCR2 (Schneider et al., 2005, Chen et al., 2008).
Both cell lines were purchased from ATCC (Manassas, VA). THP-1 cell line was
cultured in RPMI-1640 medium supplemented with 10% fetal bovine serum
(FBS) plus 1% penicillin-streptomycin (ATCC, Manassas, VA) in a humidified
atmosphere of 5% CO2 at 37˚C. SH-SY5Y cell line was cultured in 1:1
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EMEM/F12 medium with 10% FBS plus 1% penicillin/streptomycin in a
humidified atmosphere of 5% CO2 at 37˚C.
Proliferation assay. THP-1 cells (or SH-SY5Y cells) were cultured in 24
well plates (3x105cells/well, 6-8 replicates/concentration of G-CSF) for 24 hours
then G-CSF was added to THP-1 cell line in basal media of RPMI-1640 (or
EMEM/F12) + 10% FBS. 24 hours after G-CSF addition 37,000 Bq/ml
(500pmol/ml) [3H]-thymidine (Perkin-Elmer Life and Analytical Sciences, Inc., MA,
USA) was added to the cultures for 4h, then the cells were harvested, and [3H]thymidine incorporated into DNA was determined. The specific activity of [3H]thymidine was 74 Bq/pmol. Uptake was normalized based on counts per minute
(CPM) over total protein in µg and expressed as percent change from control.
Viability assay for human monocytes and human neuronal cells in
vitro. THP-1 cells were cultured in 96 well plate in basal media of RPMI-1640 +
10% FBS for 24 hours then G-CSF was added directly to wells. SH-SY5Y cells
were cultured in 24 well plates for 24h then G-CSF was added to SH-SY5Y cell
line in basal media of EMEM/F12 +10% FBS. 24h after addition of G-CSF cells
were incubated with 2µM Calcien AM (live cell dye) and 4µM Ethidium
Homodimer-1 (EthD-1) (dead cell dye) for 30min (Invitrogen, Grand Island, NY)
and analyzed using a Biotek plate reader fluorescence area scan. The
mammalian live-dead assay (Invitrogen, Grand Island, NY) assesses the integrity
of the cellular membrane (ethidium homodimer) as well as intracellular esterase
activity (calcien AM) in order to assess overall viability.
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Adhesion assay. THP-1 cells are a monocyte cell line which are not
typically very adhesive; when PMA (phorbol myristate acetate) is added to these
cells they become more macrophage-like and hence more adhesive (Shapira et
al., 1993). THP-1 cells were cultured in a 24 well plate pre-coated with fibronectin
(10ng/mL) and were treated with either basal media alone (RPMI-1640 medium +
2% FBS), G-CSF (250ng/ml) in basal media, PMA (200nM) in basal media, or GCSF+ PMA in basal media for 24h. Media was then discarded and unattached
cells were gently rinsed off with sterile 1X PBS. A total of 5 fields per well were
counted at 20x magnification under bright field microscopy (IX2 inverted
microscope; Olympus, Tokyo, Japan).
Migration assay. THP-1 cells were harvested then brought up in DMEM
media + 10% FBS. CCR-2 antagonist, RS 504393, (Tocris Biosci, Inc,
Minneapolis, MN) was used to inhibit the effect of recombinant human MCP-1
(R&D Systems, Inc., Minneapolis, MN, 279-MC) on the chemotaxis of human
monocytes. Cells were pre-treated with CCR2 antagonist in DMEM + 10% FBS
prior to start of migration assay. RS-504393 is a selective CCR-2 antagonist that
shows modest inhibitory activity in a chemotaxis assay to MCP-1. It inhibits CCR2 by occupying the CCR-2 binding site that includes acidic residue Glu291 and
specifically inhibits MCP-1 and MCP-3 signaling. This compound is not a
chemotaxis agonist and does not stimulate post receptor signaling of any kind
(Mirzadegan et al., 2000). It also binds significantly to α-adrenergic receptors
(Dawson et al., 2003). A reusable modified Boyden 48-well chamber
(Neuroprobe, Gaithersburg, MD) with a 5μM polycarbonate fibronectin coated
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filter was utilized. The top wells of chamber contained 55μL of THP-1 cell line in
DMEM media + 10% FBS and the bottom wells contained 27μL of potential
chemoattractant diluted in DMEM media +10% FBS. The plate was then
incubated for 2 hours in humidified incubator @ 37°C in 5% CO2. The number of
monocytes, which migrated to the bottom side of the filter, were quantified using
Vectashield Hardset mounting media (Vector Labs, Burlingame, CA) containing
40-6-diamidino-2-phenylindole (DAPI). All (20x) images of DAPI-labeled
monocytes (5 images/well, 6 wells per concentration) were acquired using an
Olympus BX60 microscope with an attached digital camera system (DP‐70,
Olympus, Tokyo, Japan), and the digital image was routed into a Windows PC for
quantitative analysis using ImageJ (NIH, Bethesda, MD).
G-CSF receptor parameters assessed with [125I]-G-CSF. [125I]-G-CSF
(specific activity 46.55 TBq/mmol) was purchased from Perkin Elmer (Waltham,
Massachusetts). Binding of [125I]-G-CSF was measured in previously described
method with some modifications (Kondo et al., 1991). Cells were incubated in
180 µL of binding medium containing 0.2% BSA, 5 mM MgSO4 and 50 mM
Hepes, pH 7.2 at a concentration of 1.5×107cells/ml and the appropriate
concentration of [125I]-G-CSF. Incubations were carried out at room temperature
with periodic shaking to ensure continuous mixing of cells and radioactive ligand.
The incubation time of 2 h was estimated from preliminary experiments as being
found sufficient to reach equilibrium. Nonspecific binding of [125I]-G-CSF was
measured by incubations in the presence of a 100-fold molar excess of unlabeled
G-CSF. At the end of the incubation, bound and free radio ligands were
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discriminated by using separating oil according to previously published method
(Dower et al., 1985). Namely, 80 µL aliquots were sampled from the incubation
mixture, each aliquot was layered on 300 µL of separating oil placed in 500 µL
polyethylene tubes and centrifuged for 5 min at 6000 rpm. The separating oil
consisted of 1.5 parts dibutyl phthalate and 1 part bis(2-ethylhexyl)phthalate
(Aldrich-Sigma, St. Louis, MO). Bound and free ligand activities were counted
after cutting tubes in two pieces and placing top and tip into separate scintillation
vials. Counting was performed on Beckman Coulter LS6500 scintillation counter.
Glacial acetic acid was employed to solubilize the pellet (Jordan et al., 1974).
The specific binding was determined from the amount of bound [125I]-G-CSF
blocked by competition with excess unlabeled G-CSF. The parameters of
saturation binding experiments including dissociation constant (kd), maximum
binding capacity (Bmax) and binding cooperativity (h) were calculated with
GraphPad Prism 5 software (La Jolla, CA) by using nonlinear regression
analysis.
Signal transduction triggered by G-CSF (measurement of PKCδVIII
and Bcl2 with Western blot). THP-1 cells or SH-SY5Y cells 3x106 cells in 5ml
media in a 25 cm2 flask were treated with or without 100ng/ml G-CSF for 24h.
Whole cell lysates (60mg) were separated on 10% polyacrylamide gel
electrophoresis-SDS (PAGE-SDS). Proteins were electrophoretically transferred
to nitrocellulose membranes, blocked with Tris buffered saline- 0.1% Tween 20
containing 5% nonfat dried milk, washed, and incubated with a polyclonal
antibody against either Bcl2 (Cell Signaling) or PKCδVIII-specific polyclonal
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antibody (Patel laboratory).(Jiang et al., 2008). The house keeping gene GAPDH
was used as an internal standard. Following incubation with anti-rabbit IgG-HRP,
enhanced chemiluminesence (Pierce™) was used for detection and the gels
were analyzed using UN-SCAN-IT™ software (Silk Scientific, Inc.).
Statistical analysis. In the case of western blot analysis, two-tailed
unpaired t-test was utilized, and significance was determined after 3 or more
experiments. The remaining in vitro data analyses were performed using oneway or two-way ANOVA. All data was presented as mean ± SD, except for
western blot graphs which are presented as SEM. All statistical analysis of data
was done via PRISM4 or PRISM5 statistical analysis software (GraphPad Prism,
La Jolla, CA). All comparisons were considered significant at level of P<0.05.
Results
G-CSF receptor binding kinetics in neurons differs from that in
monocytes. Increasing concentrations of radio-labeled G-CSF (alone or in the
presence of 100 fold excess “cold” G-CSF) were added to the cell cultures to
generate a saturation curve. Specific binding of [125I]-G-CSF to receptors
expressed in monocytes (THP-1 cells) and neurons (SH-SY5Y) revealed
significant differences in Kd, Bmax and number of receptors per cell (Figure 2.1).
The Kd for monocytes was 10 fold lower (greater affinity) than that in neurons.
The relationship between specific binding and concentration of the ligand was not
linear in the neuronal cultures and exhibited a Hill coefficient of 2.29, indicating
substantial cooperative binding of the ligand to receptors expressed in neurons
compared to the monocytes with a Hill coefficient of 0.92. Although there is a
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greater binding affinity in the monocytes in comparison to the neurons, there is a
5-fold greater receptor density in the neurons in comparison to the monocytes.
G-CSF treatment increases expression of anti-apoptotic proteins
Bcl2 and PKCδVIII in neurons and monocytes. G-CSF treatment activates
multiple signal transduction pathways including anti-apoptotic pathways. To
evaluate the biological response of G-CSF, the anti-apoptotic proteins Bcl2 and
PKCδVIII were measured. Protein kinase C (PKC) δ is a serine/threonine kinase
mediating cellular growth, differentiation and apoptosis. PKCδ is alternatively
spliced to generate isoforms with distinct functions in apoptosis. Human
PKCδVIII and its mouse homolog PKCδII function as anti-apoptotic proteins
(Patel et al., 2006, Jiang et al., 2008). PKCδVIII has been demonstrated to be
associated with neuronal differentiation induced by retinoic acid in human
neuroteratocarinoma (NT2) cells and promotes neuronal survival (Jiang et al.,
2008). PKCδII, the mouse homolog of PKCδVIII, is demonstrated to directly
increase the expression of Bcl2. (Apostolatos et al., 2012).
Increasing concentrations of GCSF (5.3nM or 10.6 nM) were added to the
cell culture and incubated for 24 hours. Whole cell lysates were immunoblotted
for Bcl2 and PKCδVIII. Despite the much lower binding affinity of G-CSF for
receptors borne on neurons compared to binding affinity in monocytic cells, the
biological response i.e. expression of the anti-apoptotic protein Bcl2 and
PKCδVIII, was much greater at equivalent concentrations (5.3 nM) (Figure 2.2) in
the human neuronal cell line. G-CSF, however, also increased the expression of
PKCδVIII and Bcl2 in the monocytic line at a higher concentration (10.6 nM).
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G-CSF increases DNA synthesis in both human monocytes and
neurons. G-CSF is known to stimulate proliferation of hematopoietic
stem/progenitor cells and to increase proliferation of neural stem/progenitor cells.
To compare the relative efficacy of G-CSF to stimulate cell proliferation, DNA
synthesis was measured using 3H-thymidine uptake. Addition of G-CSF to THP1 cells and to SH-SY5Y resulted in a concentration-dependent increase in DNA
synthesis that was similar in both cell lines (Figure 2.3A, 2.3B).
G-CSF treatment increases viability in neurons but not monocytes.
THP-1 cells treated with increasing concentrations of G-CSF showed no
significant difference in viability (Fig 2.4A & 2.4B), either when assessing live
cells (calcien AM positive) or dead cells (ethidium homodimer positive). G-CSF
did not improve monocyte viability, although it did increase proliferation. The
viability dye of the live-dead assay includes all healthy cells while the proliferation
assay only assesses those cells which are actively dividing; this may explain the
difference seen between the proliferative data versus the viability data in the
monocyte cell line.
SH-SY5Y cells treated with increasing concentrations of G-CSF showed a
concentration-dependent increase in viability (Fig 2.4C & 2.4D), although there
was no change in the proportion of dead cells, there was a significant increase in
the proportion of live cells at G-CSF concentrations 25 & 50ng/ml. The neuronal
cell line also had an increase in anti-apoptotic proteins at lower concentrations of
G-CSF, than the monocytic cell line, which also may explain why there is no
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significant difference in the viability of the monocytic cell line at these lower
concentrations of G-CSF.
Effect of G-CSF and MCP-1 on migration of human monocytes. To
assess whether G-CSF effects on circulating monocytes is responsible for
increased infiltration of monocytes into brain, where they contribute to the
increase in total microglia observed in earlier studies (Sanchez-Ramos et al.,
2009), an in vitro assessment of migratory capacity of the monocytes was
undertaken. MCP-1 is a known monocyte chemoattractant and therefore was
used as a standard control to compare to G-CSF to examine its potential as a
chemoattractant. At MCP-1 concentrations 5, 10, & 20ng/mL there was a
significant increase in migration of THP-1 monocytes (Figure 2.5B) across the
fibronectin coated filter, although at various concentrations of G-CSF no
chemoattractant effect was found (Figure 2.5A). Also G-CSF in combination with
MCP-1 did not result in a synergistic effect on migration of THP-1 cells (Figure
2.7).
Effect of CCR2 antagonist on migration of human monocytes.
Increased migration of monocytes triggered by MCP-1 was antagonized by preincubation with a CCR2 antagonist (20µg/ml) for 30min (Figure 2.6). Although GCSF alone did not act as a chemoattractant it was of interest to see if G-CSF
could overcome the antagonism of MCP-1 caused by CCR2 antagonist. As
shown in Figure 2.7 there was a lack of interaction between G-CSF and MCP-1in
regards to migration.
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Effect of G-CSF on adhesion on human monocytes. When PMA
(phorbol myristate acetate) is added to THP-1 cells they become more
macrophage-like and hence significantly more adhesive (Shapira et al., 1993). If
G-CSF could improve adhesion this could lead to better diapedesis and therefore
the potential for an increase migration into the brain. Unfortunately, G-CSF did
not significantly improve adhesion of THP-1 cells at various concentrations and
did not further improve adhesion caused by PMA (Figure 2.8A, 2.8B).
Discussion
Both monocytes and neurons express G-CSF receptors, but
pharmacokinetic parameters of radio-labeled ligand binding and subsequent
biological responses were markedly different. The Kd for binding of the ligand
with the neuronal G-CSF receptors was 10 fold greater (i.e. 10 fold lesser affinity)
than binding with monocyte receptors and the number of receptors per cell was 5
fold greater in the neurons. Moreover, neuronal binding exhibited significant
cooperativity, indicated by Hill coefficient of 2.29 compared to 0.92 in the
monocytic cell line. Cooperative binding refers to enhanced binding of a
ligand to a macromolecule when there are already other ligands present on the
same macromolecule. The relevance of cooperative binding to the differential
effects of GCSF in neurons and monocytes is not clear, but may reflect the fact
that G-CSF signaling in neuronal populations is predominantly of an autocrine
nature. Both the GCSF ligand and its receptor are expressed in neurons, so
autocrine signaling and cooperative binding may trigger a well-coordinated
response in a population of neurons.
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Another important distinction between the monocytes and neurons was
found in signal transduction triggered by G-CSF. The expression of the antiapoptotic proteins PKCδVIII and Bcl2 were substantially increased in the
neuronal cells, but not in the monocytic cells treated with equal, relatively high
concentrations (5.3nM). It is paradoxical that neurons exhibit a greater antiapoptotic response to G-CSF than monocytes, despite the much greater affinity
of monocyte G-CSF receptors for its ligand. Differences in G-CSF signal
transduction observed here may be attributed to variations in the structure of GCSF receptor or variations in the signaling portion of the receptor in neurons and
monocytes. It is known that spliced transcript variants of this gene occur in the
part of the G-CSF receptor gene (CSF3R) encoding the intracellular
domain of the G-CSFR (Dong et al., 1995, Germeshausen et al., 2008). It is not
known whether variations in the intracellular domain distinguish the neuronal
from monocytic G-CSF receptors, a possibility that merits further investigation.
An explanation for the differences between monocytes and neurons also
might be related to the capacity of monocytes to be replenished, in vivo, by
progenitors in the bone marrow. Mature neurons can be replaced only in limited
neurogenic niches such as the sub-ventricular zone of the hippocampus.
Therefore the survival of differentiated, mature neurons may be more dependent
on the capacity to overexpress anti-apoptotic proteins than monocytes. However,
the neuronal line used here (SH-SY5Y) maintains mitotic competency and
increases DNA synthesis in response to G-CSF treatment just as well as the
monocytes.
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Although G-CSF did not appear to directly alter migratory capacity or
cellular adhesiveness to enhance infiltration into the CNS, a course of G-CSF
administration in humans is known to increase absolute levels of circulating
monocytes in addition to total neutrophil count and hematopoietic stem cells
(CD34 cells) (Sanchez-Ramos J, 2012). This also corresponds to the in vitro data
where proliferation in a human monocytic cell line was increased with G-CSF
treatment. The mechanism of infiltration of a monocyte population from blood to
brain, differentiation into microglia and peri-amyloid plaque accumulation in AD
brains is not completely understood, but it is known that cell signaling by
monocyte chemoattractant protein (MCP-1) plays a key role. Addition of MCP-1
to monocytes, but not G-CSF, enhanced their migration through a micropore in a
cell culture migration system. G-CSF treatment did not result in an improvement
in adhesive properties, which would be helpful to monocytes undergoing
diapedesis through the endothelial cells of the BBB and into the brain. If G-CSF
does in fact enhance monocyte infiltration into the brain it does not appear to do
so by improved migratory properties, such as chemoattraction or adhesion, and
therefore it would more likely be caused by overall increase in total peripheral
monocytes or circulating hematopoietic stem cells, which may result in increased
migration through “mass action.” In other words, more monocytes in the
peripheral circulation may result in a greater extent of brain microgliosis in the
setting of neuroinflammation.
During the inflammatory process, monocyte chemotactic protein (MCP-1)
mediates the recruitment of CCR-2 expressing monocytes into the brain
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(Yamamoto et al., 2005) as well as activation of macrophages (Matsushima et
al., 1989). MCP-1 is mostly expressed in the perivascular space and brain
parenchyma during neuroinflammation (Mastroianni et al., 1998, Losy and
Zaremba, 2001, Sindern et al., 2001, Chen et al., 2003, Sorensen et al., 2004).
CCR-2 is not only expressed by monocytes but also by both neurons and
astrocytes within the brain (Banisadr et al., 2002, Gillard et al., 2002). CCR-2 is
also expressed in microvascular endothelial cells in both mice and humans
(Dzenko et al., 2001).
A potent trigger of MCP-1 release is the pro-inflammatory Aβ amyloid
peptides, which can up-regulate the release of MCP-1 (and other chemokines) in
both monocytes as well as several cells within the brain (Dawson et al., 2003).
MCP‐1 is up-regulated early in brains of transgenic mice that develop AD–like
pathology (Ishizuka et al., 1997, Sly et al., 2001, Janelsins et al., 2005,
Yamamoto et al., 2005, El Khoury et al., 2007). Elevated levels of MCP-1 have
been observed in AD patients both in microglia associated with mature senile
plaques (Ishizuka et al., 1997) and in microvessels isolated from brain cortices
(Grammas and Ovase, 2001).
The strategy of blocking the MCP‐1/CCR2 interaction has been proposed
as being effective in preventing macrophage‐induced tissue damage. Loss of
MCP-1 function is enough to impair monocyte trafficking in several inflammatory
models (Dawson et al., 2003). Mice bred to have the CCR-2 receptor knockedout (CCR-2-/-) exhibited impairment in modulating recruitment of monocytes to
areas of inflammation (Boring et al., 1997). It also was reported that cross
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breeding Tg2576 AD mice with Tg mice deficient in CCR‐2 (TgCCR‐2‐/‐) resulted
in decreased infiltration of microglia, increased plaque load and accelerated
disease progression (El Khoury et al., 2007). Another method to inhibit the MCP1/CCR-2 interaction is through pharmacological methods such as inhibition of the
CCR-2 receptor or through antibodies to MCP-1 directly. Anti-bodies to MCP-1
significantly inhibit the migration of microglia and monocytes in response to Aβstimulated macrophage supernatant in vitro (Meda et al., 1996, El Khoury et al.,
2003).
A limitation of this study is its reliance on immortalized human cell lines
that differ from mature neurons and monocytes in vivo. Some observations
reported here result from the immortal nature of the cells. For example, the
finding of increased DNA synthesis and proliferation induced by G-CSF treatment
of the neuronal line is unlikely to occur in mature differentiated neurons in vivo.
Nevertheless, there is evidence that G-CSF stimulates proliferation of neural
stem/progenitor cells of the sub-granular zone of the hippocampus both in vitro
and in vivo (Sanchez-Ramos et al., 2009). A major advantage to studying these
two cellular phenotypes in a cell culture system is the ability to isolate and control
the micro-environment for each cell population.
In summary, the cellular and molecular responses to G-CSF treatment of
monocytes suggest that neither changes in adhesiveness nor migratory capacity
are responsible for the beneficial effects of G-CSF administration in a Tg mouse
model of AD. It is clear that G-CSF treatment increases absolute monocyte count
in both mouse models of AD and human patients with AD. Therefore it is likely
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that the increased microgliosis observed in Tg AD mice treated with G-CSF is a
consequence of increased levels of circulating monocytes in the setting of Aβfueled neuroinflammation. If increased microgliosis is due to enhanced infiltration
of monocytes, it is also possible that vigorous macrophagic activity results from
the recruitment of fresh microglia to the plaques. The stimulation of DNA
synthesis along with increased anti-apoptosis observed in the neuronal cell line
might explain the previously reported improvement in hippocampal neurogenesis
and hippocampal-dependent learning seen in the AD mouse model after
treatment with G-CSF.

Figure 2.1. The saturation binding curves for radio-labeled G-CSF in neuronal and monocytic
cell lines. The results were calculated using non-linear fit and one-site specific binding with
Hill slope. (A) The neuronal cell line SH-SY5Y saturation curve reveals a Kd = 533.4 pM and
exhibits cooperative binding with a Hill coefficient of 2.29. The neuronal cell line calculated
125
results are based on the mean of 4 experiments with 3 replicates per concentration of I-GCSF within each experiment. (B) The monocytic cell line (THP-1) saturation curve reveals a
much lower Kd = 57.49 pM and a Hill coefficient of 0.92. The monocytic cell line calculated
125
results are based on the mean of 2 experiments with 3 replicates per concentration of I-GCSF within each experiment.
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Figure 2.2. Western blot of PKCδVIII and Bcl2 expression in human neuronal (SH-SY5Y)
and monocytic cell lines (THP-1) incubated with G-CSF for 24h. Both PKCδVIII and Bcl2
expression are increased in the neuronal cells (100ng/ml & 200ng/ml; 5.3nM & 10.6nM),
and in the monocytic cells (200ng/ml; 10.6nM). The above graphs (B) & (D) show PKCδII
or Bcl2 percent densitometric units normalized to GAPDH, and represent the results of
three separate experiments. The results were analyzed with two-tailed Student’s t-test,
*** = p<0.0001.
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(B)
Figure 2.3. G-CSF increased DNA synthesis of human monocytes (THP-1) and
human CNS neurons (SH-SY5Y). (A) THP-1 cells treated with concentrations
of G-CSF 25, 50 & 100 ng/mL had a significant increase in thymidine
incorporation (DNA synthesis) (n=6 replicates per G-CSF concentration, oneway ANOVA, *=p<0.0001 ). (B) SH-SY5Y cells treated with concentrations of
G-CSF 25, 50, & 100ng/mL had a significant increase in thymidine
incorporation (DNA synthesis) (n=8 replicates per G-CSF concentration, oneway ANOVA *=p<0.0001).

(C)
(D)
Figure 2.4. Effect of G-CSF on THP-1 and SH-SY5Y viability (A)&(B)
There was no statistical significant difference in RFU emitted by dead
cells or by live cells at any of the G-CSF treatment concentrations in
THP-1 cell line (n=6 replicates per G-CSF concentration, one-way
ANOVA, p=0.6921). Therefore G-CSF has no effect on the viability of
this monocytic cell line (THP-1). (C)&(D) There was a significant
difference in RFU emitted by live cells at 25 & 50 ng/mL of G-CSF
treatment concentrations in SH-SY5Y cell line (n=10 replicates per GCSF concentration, one-way ANOVA, *=p<0.0001). Therefore G-CSF
has a significant effect on the viability of this neuronal cell line (SHSY5Y).
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Figure 2.5. MCP-1, but not G-CSF served as a chemoattractant for human
monocytes (THP-1 cell line). (A) Migration of monocytes was not elicited by
G-CSF at various concentrations (G-CSF added to lower wells of migration
assay) (n=6 replicates per G-CSF concentration, one-way ANOVA,
p=0.2430). (B) MCP-1 stimulated cell migration in a concentration-dependent
manner through a 5µm fibronectin coated filter over a 2h period (n=6
replicates per MCP-1 concentration, one-way ANOVA, *=p< 0.0001).

Figure 2.6. Increased migration of monocytes triggered by MCP-1 was
antagonized by pre-incubation with a CCR-2 antagonist. Monocytes
(THP-1 cells) were pre-incubated with CCR-2 antagonist (20µg/mL) for
30min (n=6 replicates per treatment, two-way ANOVA,*=p<0.0001).
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(A)
(B)
Figure 2.7. Lack of interaction of G-CSF with MCP-1 in stimulating
migration. (A) MCP-1, but not G-CSF significantly increased migration
from control/media alone (n=6 replicates per treatment, one-way ANOVA,
p<0.001). Addition of G-CSF to media containing MCP-1 had no effect on
migration of THP-1 cells. (B) Pre-incubation with CCR-2 antagonist
prevented the increase in migration caused by MCP-1 (20ng/mL) and
addition of G-CSF did not prevent the inhibition of migration (n=6
replicates per treatment, one-way ANOVA, p>0.05).

(B)
(A)
Figure 2.8. Effect of G-CSF on cellular adhesiveness (THP-1). (A) THP-1 cells
were treated with a range of G-CSF concentrations in a 24 well plate pre-coated
with fibronectin (n=6 replicates per treatment, one-way ANOVA, *=p<0.0001). GCSF did not significantly improve adhesion of THP-1 cells. PMA was used as a
positive control. (B) Addition of G-CSF to PMA did not increase or decrease
cellular adhesiveness elicited by PMA (n=6 replicates per treatment, one-way
ANOVA, *=p<0.0001).
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Chapter 3: Effect of G-CSF on GFP+ BMDCs in a chimeric AD mouse model
Abstract
G-CSF has been reported to increase microgliosis and decrease amyloid
burden in a mouse model of AD. The objective of the present study was to
determine the extent to which effects of G-CSF on mouse bone marrow derived
cells (BMDC) are responsible for the beneficial effects seen in the AD mouse
model. Method: Transgenic (Tg) green fluorescence protein (GFP) mouse BM
was harvested and incubated with or without G-CSF in vitro to determine if the
cytokine changes the proportion of BMDC of monocytic lineage and that express
GFP. To assess the effects of G-CSF in vivo and to study its influence on
infiltration of cells of monocytic lineage into brain, non-transgenic (NT) and
APP+PS1 Tg chimeric mice (with GFP+ BMDC) received subcutaneous (s.c)
injections of G-CSF or vehicle every other day for a total of 8 injections. The
following parameters were measured: percentage of GFP+ and GFP+CD11b+
doubly-labeled BM cells in vitro; the total number of GFP+ BMDC as well as the
percentage of microglia and amyloid burden in the hippocampus (HC) and
entorhinal cortex (EC) in chimeric NT & Tg AD mice in vivo. Results: G-CSF
increased the percentage of both GFP+ cells and GFP+CD11b+ BM cells in vitro.
Despite the increase in microgliosis and decrease in β-amyloid burden observed
in the hippocampus after G-CSF treatment in the chimeric Tg mice, there was no
difference in the migration of GFP+ BMDC into the capillaries of the brain in
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either the HC or EC, and no GFP+ cells were found within the brain parenchyma.
Conclusions: The percentage of GFP BM cells of monocyte lineage are
increased under in vitro conditions, although it is unclear if BMDC are
responsible for the beneficial effects of G-CSF administration in a Tg mouse
model of AD. It is likely that the increased microgliosis observed in chimeric Tg
AD mice treated with G-CSF is a consequence of increased proliferation of
endogenous perivascular or parenchymal microglia in the setting of Aβ-fueled
neuroinflammation and the decrease in β-amyloid burden is due to improved
clearance by newly generated microglia, although the direct effect of G-CSF on
microglial cells will need to be further assessed.

Introduction
Embryological origins of microglia. The exact origins for the various
subtypes of microglia are not yet completely understood. During embryogenesis
microglial are derived from either “neuroectodermal” or neuroepithelial origins,
similar to that of astrocytes (Richardson et al., 1993, Eglitis and Mezey, 1997,
Fedoroff et al., 1997), or “myeloid-monocytic” origins, such as a
myeloid/mesenchymal progenitors from yolk sac (Hickey et al., 1992, Ling and
Wong, 1993, Chan et al., 2007, Soulet and Rivest, 2008). It is proposed that the
parenchymal microglia are derived from the neuroectodermal matrix, while most
likely perivascular microglia and macrophages in the central nervous system
(CNS) are derived from myeloid progenitors from the yolk sac. However, greater
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than 95% of microgliosis occurs postnatal or after the formation of the blood brain
barrier (BBB) (Soulet and Rivest, 2008).
Adult origins of microglia. During adulthood there are several proposed
theories of microglial turnover. One hypothesis postulates microglia self-replicate
or proliferate in the CNS (Soulet and Rivest, 2008). Another hypothesis
postulates that circulating monocytes, or precursor cells/bone marrow stem cells
(BMSC), infiltrate across the BBB and the precursors become parenchymal or
perivascular microglial or macrophages within the CNS (Lawson et al., 1992,
Eglitis and Mezey, 1997, Priller et al., 2001, Hess et al., 2004, Simard and
Rivest, 2004, Simard et al., 2006). This hypothesis may have some flaws
because microglia have more immature cell markers than circulating monocytes,
or are not as terminally differentiated as mature circulating monocytes.
Therefore, it may be only circulating precursor cells, and not mature monocytes,
that can become microglia (Alliot et al., 1991, Kennedy and Abkowitz, 1997,
Carson et al., 1998, Kennedy and Abkowitz, 1998, Santambrogio et al., 2001,
Simard and Rivest, 2004, Davoust et al., 2006).
Function and characteristics of microglia. Microglia are the immune
monitoring cells of the CNS. Microglia are constantly scanning the brain for
changes and rapidly respond to these changes, such as infection, inflammation,
trauma, tumors, and neurodegeneration (Kreutzberg, 1996). Microglia are also
known as the resident macrophages of the CNS and therefore have phagocytic
properties (Perry and Gordon, 1988, Kreutzberg, 1996, Kempermann and
Neumann, 2003). Morphological differences distinguish parenchymal microglia
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which have a ramified morphology, and perivascular microglia, amoeboid cells
which reside near blood vessels/capillaries. The grey matter in the brain has a
greater proportion of microglia than the white matter (Lawson et al., 1990, Soulet
and Rivest, 2008); also the microglia in the grey matter have a round cell body
and branched processes, while the microglia in the white matter have an oval cell
body and fewer processes (McKay et al., 2007).
Resting and activated microglia. Resting microglia have short spiny
projections and little cytoplasm or are ramified in shape (Lawson et al., 1990,
Barron, 1995). When microglia become activated, their shape becomes more
amoeboid with abundant cytoplasm, and they express the MHC II marker
(Barron, 1995). Activated microglia proliferate more rapidly, migrate to the area of
pathogenesis or trauma, resemble a more macrophage-like morphology and may
release cytokines, which may be protective (anti-inflammatory) or cytotoxic
(inflammatory) (Kreutzberg, 1996).
Role of microglia in neurodegenerative diseases. Several hypotheses
have been proposed to explain the behavior of microglia during
neurodegenerative diseases. In the “neuro-inflammatory hypothesis”, β-amyloid
peptides act directly on the microglia causing a release of inflammatory
cytokines, reactive oxygen species (ROS), and nitrous oxide (NO) which can
result in neurodegeneration (Oken, 1995, Kempermann and Neumann, 2003).
Therefore, in this hypothesis, activation of microglia by β-amyloid results in
deleterious effects on neurons in the CNS. In the “non-cell-autonomous
hypothesis”, β-amyloid peptides act directly on astrocytes and neurons inflicting
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damage, causing the release of cytokines and chemokines which act both on
each other as well as activate microglia, which result in further inflammation and
neurodegenerative effects (Lobsiger and Cleveland, 2007, Ilieva et al., 2009). In
the “microglial dysfunction hypothesis”, it is not about the negative effects of
microglia, but the lack of the positive effects of microglia, meaning β-amyloid
peptides act on microglia overtime eventually causing them to become dystrophic
and unable to release the necessary cytokines, enzymes and growth factors the
neurons need to survive (Gebicke-Haerter et al., 1996, Simard and Rivest, 2007,
Farfara et al., 2008). In reality not one hypothesis is entirely correct and it is
probably a combination of the hypotheses that correctly explain how microglia
react in a neurodegenerative situation, such as AD (Polazzi and Monti, 2010).
Clearance of β-amyloid by microglia. In the AD brain as well as in the
aging brain there is an increase in reactive or activated microglia (Carpenter et
al., 1993, Barron, 1995). These microglia help mediate the clearance of βamyloid through phagocytosis (DiCarlo et al., 2001, Britschgi and Wyss-Coray,
2007, Herber et al., 2007). Although in aging and neurodegenerative diseases
microglial phagocytosis becomes impaired (Marx et al., 1998, Rogers et al.,
2002, Lucin and Wyss-Coray, 2009). Therefore although the amount of microglia
is increasing, they become less effective at clearing β-amyloid as the disease
progresses.
Tracking of BMDCs from periphery to brain. Proliferation of microglia
within the brain occurs both through the self-renewal of parenchymal microglial
as well as a contribution from circulating peripheral precursor cells (Davoust et
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al., 2006, Soulet and Rivest, 2008). Circulating peripheral cells can undergo
diapedesis across the BBB into the brain parenchyma (Priller et al., 2001, Hess
et al., 2004, Simard and Rivest, 2004). BM supplies approximately ten percent of
the normal adult brains microglia, brain immune cells, and this amount increases
in the injured brain, such as in Alzheimer’s Disease (AD) (Bowling et al., 1993, Ip
and Yancopoulos, 1994, Hess et al., 2002, Sanchez-Ramos et al., 2008). The
importance of the migration of BMDC into the brain is their contribution to the
repair of neural cells in degenerative diseases, such as in AD as well as in stroke
and traumatic brain injury (Stalder et al., 2005, Simard et al., 2006). To
distinguish blood-derived microglia from resident microglia within the brain, GFP
chimeric mice are often utilized (Furuya et al., 2003). These GFP chimeric mouse
models have been useful in the study of neurodegenerative diseases, such as
Parkinson’s Disease (PD) and AD (Hess et al., 2004, Kokovay and Cunningham,
2005, Malm et al., 2005, Simard et al., 2006, Mildner et al., 2007, Rodriguez et
al., 2007, Mildner et al., 2011).
Research Rationale
In a previous study done by the Sanchez-Ramos laboratory, G-CSF
treatment in an AD mouse model resulted in increased microgliosis, decreased
β-amyloid burden, enhanced neurogenesis and improved behavior in the radial
arm water maze (RAWM) (Sanchez-Ramos et al., 2009). The mice utilized to
demonstrate these disease-modifying effects were not GFP chimeric and
therefore the contribution of BMDC to the increase in microgliosis or β-amyloid
plaque clearance could not be assessed. The purpose of the present research is
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to elucidate the effects of G-CSF on the infiltration of peripherally circulating
BMDC into the AD mouse brain in vivo and to assess the effect of G-CSF directly
on GFP Tg mouse BM cells in vitro.
Materials & Methods
Animals. AD mice were generated from a cross between F6 generation
mice heterozygous for the mutant APPK670N, M671L gene (i.e. the APPsw,
Swedish mutation derived from Tg2576 mice), and littermate mutant PS1 (6.2
line) mice bearing the M146V mutation (all mice contained a mixed background
of C57B6, B6D2F1, SJL, and SW). Mice were initially genotyped at the time of
weaning and then had a confirmatory genotyping at 6 weeks of age. A total of 9
APP-PS1 double Tg mice (e.g. mice bearing both APPsw and PS1 mutations)
and 6 non-Tg (NT) littermates were utilized to generate chimeric mice with GFPexpressing bone marrow. GFP mice were generated from a cross between Tg
GFP mice (C57BL/6-Tg [ACTB-EGFP] 1Osb/J, 003291) and C57BL/6 mice (the
Jackson Laboratory, Bar Harbor, ME, USA). GFP mice were confirmed with
blood smears taken at time of weaning. Microscopic examination of blood
smears from tail clippings were analyzed for the presence of green fluorescence
(GFP expression) in leukocytes. All mice were housed and maintained in
standard laboratory cages in a temperature and humidity controlled room in a
specific pathogen free facility under a 12-h light/dark cycle with light onset at 6:30
AM, with ad libitum access to rodent chow and water. All experiments conformed
to guidelines for the ethical use of animals as provided by the Association for the
Assessment and Accreditation of Laboratory Animal Care, International
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(AAALAC #000434). The protocol was approved by the IACUC of the University
of South Florida.
Generation of Chimeric Tg APP/PS1 mice. The APP-PS1 and NT mice
(4 months old) were lethally irradiated with 800 rads total body irradiation,
delivered in two fractions four hours apart, each fraction 400 rads was given at
dose rate of 106 rads/min in a Gammacell 40 Extractor (Nordion International,
Inc., Ontario, Canada) (Furuya et al., 2003)). Approximately 2 h later, irradiated
mice were rescued with a bone marrow transplant of 1x107 mononuclear cells in
0.2 ml from Tg GFP mice (C57BL/6-Tg [ACTB-EGFP] 1Osb/J, 003291; the
Jackson Laboratory, Bar Harbor, ME, USA) infused via tail vein. Bone marrow–
derived cells in the rescued mice were readily tracked by virtue of their green
fluorescence. Examination of blood smears from tail clippings for the presence
of green monocytes confirmed successful engraftment. 100% of the irradiated
mice had successful engraftment and exhibited GFP mononuclear cells in their
peripheral blood.
G-CSF treatment of mouse GFP BM cells. BM was harvested and
pooled from both the tibia and femurs of eight Tg GFP mice (C57BL/6-Tg [ACTBEGFP] 1Osb/J, 003291; the Jackson Laboratory, Bar Harbor, ME, USA). BM
cells were cultured in 75cm2 flasks in DMEM media + 10% FBS (with or without
G-CSF 250ng/ml). After culturing for 24h cells were harvested from flasks,
filtered through a 40 μm nylon cell strainer (BD Labware, Bedford, MA, USA) to
remove particulate matter, red blood cells were lysed using 1X RBC lysis buffer
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(Ebioscience, San Diego, CA), cells were rinsed in phosphate buffered saline
(PBS) three times, then diluted in PBS and counted using a hemocytometer.
Fluorescence activated cell sorting (FACS) of mouse GFP BM cells.
Cells were incubated for 15min on ice with Fc blocking CD16/CD32 (BD
Pharmingen, San Jose, CA, USA), washed with PBS, and incubated for 30min
on ice with APC Rat Anti-Mouse CD11b (clone M1/70) antibody (BD
Pharmingen, San Jose, CA). CD11b+ is a cell marker commonly expressed by
monocytes. Cells were then washed twice in PBS. Cells were stained with
propidium iodide (PI) to exclude dead cells. Cell samples were analyzed (in
replicates of three) with Accuri Cytometer (Accuri Cytometers, Ann Arbor, MI) to
quantify the percentage of live cells that are GFP+ and GFP+CD11b+. 100,000
events were run for each sample. Gating was used to exclude debris and dead
cells.
G-CSF dose and administration schedule in AD chimeric mice. GCSF, a natural human glycoprotein, exists in two forms of a 174-and 180-aminoacid-long protein of molecular weight 19,600 g per mol. The more-abundant and
more-active 174-amino acid form has been used in the development of
pharmaceutical products by recombinant human DNA (rhDNA) technology.
Filgrastim (Neupogen®, Amgen, Inc., Thousand Oaks, CA, USA), one of three
proprietary G-CSF compounds, was utilized in the present study. The dose of GCSF (250 μg/kg x 8 doses) administered in the present study was determined
based on the dose used in the previous study published by the Sanchez-Ramos
laboratory (Sanchez-Ramos et al., 2009), in which this dose significantly
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decreased Aβ plaque formation, increased microgliosis and improved
neurogenesis and behavior in radial arm water maze (RAWM). This dose is lower
than that reported to be effective in mobilizing bone marrow in a rat model of
stroke (300μg/kg x 10 days), but higher than that utilized by others in rodent
models of stroke (Schabitz et al., 2003, Six et al., 2003, Solaroglu et al., 2006)
and in a published report on the treatment of memory impairment in a mouse
model of AD (50 μg/kg s.c. for 5 days) (Tsai et al., 2007).
The schedule of administration of G-CSF was one subcutaneous (s.c.)
injection every other day over two and a half weeks. G-CSF was diluted in 5%
dextrose at a 1/20 dilution as recommended by the manufacturer (Amgen, Inc.).
Vehicle (5% dextrose) was administered to control groups for both Tg and NT
mice.
Immunohistochemistry. At the conclusion of the treatment mice were
euthanatized using an intraperitoneal (i.p.) injection of 0.05-0.1ml somnasol, then
receiving a 100-200 unit injection of heparin into the heart, followed by
transcardial perfusion of 0.9% saline (~40ml/mouse) followed by four percent
paraformaldehyde (PFA) (~20ml/mouse). Brains were then removed from skull
and fixed in 4% PFA for 24h; the right hemisphere of the brain then was
transferred to 30% sucrose solution for 4 days at 4˚C for immunofluorescence.
After incubation in 30% sucrose solution the right hemisphere was frozen in
isopentane on dry ice then transferred to -80˚C freezer. The right hemispheres
were then transferred to the cryostat (set at -20˚C) (Leica, Germany) one hour
prior to sectioning the brains to allow them to equilibrate in temperature, then
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brains were sectioned coronally using the cryostat at 30μM in a 1:6 series and
stored in 24-well plates in a cryoprotectant/antifreeze solution at (-20 to -18˚C).
Prior to immunofluorescence staining sections were washed three times in 1X
PBS then place in a blocking solution (PBS+ 10% normal donkey serum, 3%
bovine serum albumin (BSA), & 10% Triton-X 10X) for one hour at 4˚C on maxi
rotator and incubated for 24 hours at 4˚C in an primary antibody cocktail of
chicken anti-GFP (1:500, Millipore, Billerica, MA) plus rabbit anti-Iba1 (1:1000,
Wako, Osaka, Japan). Sections were washed in PBS and incubated for one hour
at room temperature in a secondary antibody cocktail of donkey anti-chicken
FITC (1:400, Millipore, Billerica, MA) plus donkey anti-rabbit IgG Alexa Fluor 594
(1:1000, Invitrogen, Grand Island, NY) and coated with Vectashield mounting
medium with DAPI (Vector Laboratories, Burlingame, CA). Labeled cells were
visualized with fluorescence microscopy (IX2 inverted microscope; Olympus,
Tokyo, Japan) using appropriate filters. Digital images were captured with the
DP-70 digital camera system (Olympus).
The left hemisphere was routinely embedded in paraffin with 24 h
processing. For paraffin sectioning, five coronal sections (per set) with a 150 μm
interval were cut at a thickness of 5 μm in hippocampus (HC) and entorhinal
cortex (EC), bregma -2.92 to -3.64 mm (Paxinos G, 2001). Four sets of five
sections from H and EC were prepared for analyses of Aβ plaque and Iba1
(ionized calcium-binding adapter molecule 1). Immunohistochemical staining was
performed following the manufacturer’s protocol using a Vectastain ABC Elite kit
(Vector Laboratories, Burlingame, CA, USA) coupled with the diaminobenzidine
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(DAB) reaction, except that the biotinylated secondary antibody step was omitted
for Aβ immunohistochemical staining. The following primary antibodies were
used for immunohistochemical staining: a biotinylated human amyloidβmonoclonal antibody (clone 4G8;1:200, Covance Research Products,
Emeryville, CA, USA) and an Iba-1 polyclonal antibody (1:1000, Wako, Osaka,
Japan).
Quantification of Immunofluorescence. GFP+ labeled cells were
estimated using every 6th section taken throughout the hippocampus and
entorhinal cortex (every 180 microns). To avoid counting partial cells a
modification to the optical dissector method was used so that cells on the upper
and lower planes were not counted. The number of GFP+ cells counted in every
6th section was multiplied by 6 to get the total number of GFP+ cells in the
hippocampus (HC) or the entorhinal cortex(EC) (Shors et al., 2002).
Quantification of Bright Field Immunohistochemistry. Images of DAB
stained sections were acquired as digitized tagged-image format files to retain
maximum resolution using an Olympus BX60 microscope with an attached digital
camera system (DP-70, Olympus), and digital images were routed into a
Windows PC for quantitative analyses using SimplePCI software (Compix, Inc.
Imaging Systems, Cranberry Township, PA, USA). Images of five sections (each
5 μm thick and 150 μm apart) were captured from serially sectioned EC and HC
and a threshold optical density was obtained that discriminated staining from
background. Each anatomic region of interest was manually edited to eliminate
artifacts. For Aβ and Iba1 (microgliosis) burden analyses, data was reported as
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the percentage of labeled area captured (positive pixels) divided by the full area
captured (total pixels). Bias was eliminated by analyzing each entire region of
interest (HC and EC) represented by the sampling of five sections per region.
Stereological equipment was not used. Each analysis was done by a single
examiner blinded to sample identities.
Statistical Analysis. An unpaired two-tailed (or Student’s) t-test was used
to evaluate the effect of G-CSF on pooled GFP bone marrow cells in vitro. While
an unpaired one-tailed t-test was used to evaluate β-amyloid burden as well as
Aβ 1-40 and Aβ 1-42 plasma levels; a one-tailed t-test was able to be utilized due
to the expected result of G-CSF to decrease, and not increase, Aβ load based on
previous results (Sanchez-Ramos et al., 2009). Two-way analyses of variance
(ANOVA) were used to evaluate the effects of G-CSF (treatment) on microgliosis
(percent Iba1) as well as total GFP positive cells in the HC and EC of NT and Tg
AD mice (genotype). When appropriate, post hoc analyses, such as Bonferroni
Multiple Comparison test, were used to isolate drug effects from genotypic
effects. All statistical analyses were determined significant at the 0.05 alpha
levels. Data was presented as mean ± standard deviation (SD).
Results
Effects of G-CSF on Tg GFP mouse bone marrow cells in vitro.
Examination of the BM harvested from Tg GFP mice revealed that less than half
of the nucleated cells in the BM were GFP. Approximately 43 percent of the
basal media-treated BM cells expressed GFP and this proportion was
significantly increased to approximately 52 percent with G-CSF treatment (Figure
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3.1A). Also of importance was the percentage of GFP+ cells that have the
propensity to migrate into the brain, or those cells of monocyte/myeloid lineage,
CD11b+. G-CSF treatment (250ng/ml) for 24 h significantly increased the
percentage of GFP+CD11b+ BM cells from approximately 21 percent to 29
percent (Figure 3.1B).
Effects of G-CSF on β-amyloid burden, β-amyloid plasma levels, and
microgliosis in the chimeric AD mouse brain. In order to assess the effect of
G-CSF on β-amyloid burden, β-amyloid plasma levels and microgliosis in 8mo
old chimeric AD mice; chimeric NT (n=4) and Tg AD mice (n=5) were treated with
s.c. injections of G-CSF or vehicle every other day for a total of 8 injections.
Treatment with G-CSF resulted in a significant decrease in the percentage of βamyloid burden (4G8) in the HC, but not the EC, in the chimeric Tg AD mice
(one-tailed unpaired t-test P<0.05) (Figure 3.2A), although there was no
significant change in either Aβ 1-40 or Aβ 1-42 plasma levels with G-CSF
treatment (Figure 3.2B). Total microgliosis was measured using the marker Iba1,
which labels both resting and activated microglia, in both the HC and the EC.
There was a significant genotypic effect on microgliosis, in which Tg AD mice
had significantly increased levels of microgliosis in the HC and EC in comparison
to the NT littermates (two-way ANOVA, P<0.0001). G-CSF treatment significantly
increased microgliosis in Tg AD mice in the HC, but not the EC, although did not
have a significant impact on microgliosis in NT AD mice (two-way ANOVA,
P<0.01) (Figure 3.2C & 3.2D).

87

Effects of G-CSF on migration on GFP+ cells into the chimeric AD
mouse brain. GFP+ cells migrated to the blood vessels (BV) of the HC and the
EC as well as the choroid plexus of brain in chimeric NT & Tg AD mice, but did
not migrate into the brain parenchyma in either the HC or the EC (Figure 3.3). GCSF did not significantly increase migration of GFP+ cells into the BV of either
the HC or the EC, also there was no significant genotypic effect on GFP+
migration between the Tg and NT AD mice (Figure 3.4).
Discussion
The proportion of GFP positive cells harvested from chimeric Tg GFP
bone marrow was 43 percent of the total nucleated cells, and G-CSF treatment
increased this proportion increased by almost 10 percent. This finding has
several implications for studies using this similar chimeric mouse models for
tracking and following the phenotypic fate of GFP-labeled BMDC. Without
knowing the proportion of GFP+ cells that compose the BM of each chimeric
mouse, results from these experiments might lead to incorrect conclusions. For
example, if a difference in the numbers of GFP positive cells found in brain
following a particular drug treatment is found, it would be unclear if the difference
in GFP+ cells within the brain was due to the treatment administered, or to a
difference in proportion of GFP+ BM cells in the bone marrow compartment of
the treatment group of mice. Hence, studies showing significant differences in
BMDC infiltration should be examined with this caveat in mind. To interpret this
data correctly and to perform comparisons, one would need to normalize the
number of infiltrated cells to the proportion of labeled cells. In this study we did
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not normalize the proportion of GFP labeled cells in the brain to that within the
BM, but this normalization will be done in future studies.
Unexpectedly, GFP+ cells were not found in the brain parenchyma of the
chimeric GFP Tg APP/PS1 mice or NT mice regardless of the proportion of GFP
positive cells in the bone marrow. Reviewing other studies of chimeric GFP mice,
we found a report in which irradiated AD mice, with “shielded” heads, did not
result in infiltration of GFP+ cells into brain parenchyma of the mice, but only into
blood vessels within the brain (Mildner et al., 2011). Although the mice in this
study did not have their heads “shielded” they received a lower dose of irradiation
800rads (split into two doses), while the “non-shielded” and “shielded” mice in the
Mildner et al. study received 1100rads (in a single dose) as well as experienced
a change in fur depigmentation that was not noted in the current study (Mildner et
al., 2007, Mildner et al., 2011). The “unshielded” AD mice in the Milder et al.
study resulted in GFP+Iba1+ cells within the brain parenchyma both in the cortex
and HC; in other words GFP+ BMDC that differentiated into microglia. The higher
dose of irradiation in the “unshielded” mice, in the Mildner et al. study, may have
affected BBB permeability resulting in a greater influx of BMDC into the
parenchyma (Mildner et al., 2011). However, GFP+CD11b+ circulatory cells have
been shown to enter the CNS of APP+PS1 Tg AD mice without irradiation and
also become GFP+Iba1+ cells within the brain parenchyma (Lebson et al., 2010).
Therefore, the exact conditions that result in infiltration of BMDC into the brain in
the AD mouse model are unclear. In addition, the present study did not reveal
differences in GFP positive BMDC within capillaries in both the HC and EC of the
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Tg and NT chimeric AD mice, regardless of treatment. Another point to mention
is that BM cells migrate into other organs within the AD mice besides the brain,
as in vivo GFP BM cells also have been found to migrate into the blood, spleen
and pancreas (data not shown). Therefore the combination of the GFP BM cells
containing less than fifty percent GFP positive cells and the migration of these
BM cells to various organs throughout the body may contribute to the lack of
detection of GFP cells in the brain parenchyma. It will be important to select a
transgenic GFP mouse with a higher percentage of GFP BM for future studies.
Even though there was no change in BMDC infiltration into the brain, a
significant increase in microgliosis as well as a significant decrease in β-amyloid
burden was found in the HC of chimeric Tg AD mice (Figure 3.2). As this
increase in microgliosis could not be attributed to BMDC, the microgliosis is likely
a result of direct stimulation of resident microglia by G-CSF. G-CSF is known to
cross the BBB (Zhao et al., 2007) and microglia are known to express the GCSFR (Hasselblatt et al., 2007). Unfortunately the pharmacokinetics of G-CSF
ligand binding to receptors on microglia and the direct actions of G-CSF on
microglia in vitro were not determined here at this time.
Previous in vitro studies of rat microglia treated with G-CSF over 48-72 h
did not report effects on microglial proliferation measured by tritiated
thymidine(Giulian and Ingeman, 1988). Ameboid microglial phagocytosis in vitro
and in vivo was also not improved with G-CSF treatment (Giulian and Ingeman,
1988). In stroke-induced rats, G-CSF treatment increased microgliosis in the
uninjured CNS (Iba1+BrdU+ cells) and bone marrow derived microglia
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(GFP+Iba1+ cells) were found both in the uninjured and injured CNS, but the
extent of BMDC infiltration into the brain was not increased with G-CSF treatment
(Bartolini et al., 2011). G-CSF treatment increases migration of SOD-1 mouse
microglia in vitro and a significant increase in microgliosis in the spinal cords of
G-CSF treated ALS mouse model in vivo(Yamasaki et al., 2010). The increase in
microgliosis seen in various animal models of neuroinflammation or
neurodegeneration with G-CSF treatment can potentially be caused by effects
both on circulating BMDC and endogenous microglia. In the present study, it is
difficult to determine which mechanism is the major contributor as less than half
of the BMDC in Tg green mice express GFP and the percentage of GFP+ BM
cells in the chimeric AD mice as well as the direct effects on microglia were not
assessed. The decrease in β-amyloid burden could potentially be due to
clearance by activated microglia engulfing the plaques as well as the clearance
of β-amyloid by perivascular macrophages.
A weakness of this study is a very small number of both NT and Tg AD
mice were used (n=1-3 mice per group), and therefore both a genotypic effect
and a treatment effect of G-CSF on GFP+ cell migration may be seen with a
larger number of mice. Due to the small N in this study a power analysis was
performed to determine the sample size of animals that would be necessary in
future studies to detect a difference based on the current studies variability. It
was determined that an N of 8 animals per group will be necessary to detect a
significant difference between the means with an alpha = 0.05 and beta= 0.80.
Also in future chimeric mouse studies it will be of interest to assess the
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proportion of GFP+ cells in the BM compartment in comparison to those GFP+
cells that migrate into the brain, to isolate the true drug effects on migration from
those effects due to “mass action” of an increase in number of cells in the BM
compartment.
In conclusion, the effect of G-CSF on BMDC in a mouse model of AD is
still unclear. The ability of G-CSF to increase the percentage of GFP+ and
GFP+CD11b+ BM cells in vitro as well as the increase in microgliosis in the
hippocampus of chimeric Tg AD mice may contribute to a more rapid turn-over of
fresh perivascular and parenchymal microglia, which have not yet been exposed
to chronic assault by β-amyloid peptides. This is important as Tg AD mice have
been shown to exhibit reduced expression of Aβ-binding receptors and Aβdegrading enzymes resulting in dysfunctional microglia (Hickman et al., 2008).
The combined effect of G-CSF on both BMDC as well as endogenous microglia
could result in improved clearance of β-amyloid, which would explain the
significant decrease in hippocampal β-amyloid burden found in Tg chimeric AD
mice.
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Figure 3.1. G-CSF increases the percentage of GFP+ and GFP+CD11b+
mouse BM cells. BM cells were harvested and pooled from 8 GFP mice,
then incubated for 24h with or without G-CSF 250ng/mL. (A) The
percentage of total GFP+ cells significantly increased (paired t-test twotailed, *p=0.003) after treatment with G-CSF. (B)The percentage of doublepositive GFP+CD11b+ cells significantly increased (paired t-test two-tailed,
*p=0.005) after treatment with G-CSF.
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Figure 3.2. Effect of G-CSF on β-amyloid burden, Aβ plasma levels and microgliosis in
chimeric NT & Tg AD mice. (A & D) G-CSF significantly decreased amyloid plaque burden in
the HC , but not the EC (n=2-3 mice per treatment group, one-tailed unpaired T-test,
*P=0.03). (B) G-CSF did not have a significant effect on plasma Aβ levels (C) Tg AD mice
have significantly more microgliosis (Iba1immunoreactivity) in both the HC & the EC than NT
littermates. G-CSF increased Iba1 immunoreactivity in the HC (E), but not the EC (image not
shown) in Tg AD mice (n=2-3 mice per treatment group, two-way ANOVA, *P<0.01). This
data is comparable to that seen in non-irradiated 8mo NT and Tg AD mice used in the
neurogenesis experiments (see Chapter 4).
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(C)
Figure 3.3. Fluorescence captured images (20X) of GFP+ (green), Iba1+ (red) and DAPI (blue)
cells in BVs of various regions of the brain. (A) Images of GFP+ cells in capillaries of the HC, (B)
of the EC, and (C) of the choroid plexus.
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Figure 3.4. The effect of G-CSF on migration of GFP+ cells from the BM to
the BVs of the HC and the EC. There was no significant genotypic effect or
significant G-CSF treatment effect on migration of GFP+ cells to either the
BVs of the HC or the EC (n=1-3 mice per treatment group, two-way
ANOVA, p=0.35 (HC), p=0.56 (EC).
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Chapter 4: Effect of G-CSF on Neurogenesis in an AD mouse model
Abstract
G-CSF has been reported to promote neurogenesis both in vitro and in
vivo mouse model of AD. The objective of the present study was to further
identify the effect of G-CSF on neural stem/progenitor cell proliferation and
neurogenesis in a normal and AD mouse model. Methods: Flow cytometry was
used to quantify numbers of BrdU+ and double-labeled (BrdU+/NeuN+) cells in
the hippocampi of a wild-type and AD mouse model with and without G-CSF
treatment. Brdu+ and DCX+ cells were also counted in the DG of the HC using
fluorescence immunohistochemistry in G-CSF or vehicle treated AD and in NT
mice. Synaptophysin in CA1 region of HC, amyloid and microglial burden in both
HC and EC were determined using biotinylated immunohistochemistry. Results:
In normal ICR mice G-CSF significantly increased proliferation of stem/progenitor
cells and generation of new neurons in the SGZ of the HC as determined via
FACS. Using immunohistochemistry for quantification, DCX+ counts in the SGZ
of the HC of APP/PS1 mice treated with G-CSF were increased to NT mouse
levels. Synaptophysin density in the CA1 region was significantly increased in
both NT and APP/PS1 mice after G-CSF treatment. Amyloid burden (4G8) was
significantly decreased while microgliosis (Iba1) was significantly increased in the
HC of APP/PS1 G-CSF treated mice. Conclusions: G-CSF has direct effects on
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the AD brain, 1) direct effects of G-CSF on microglia improve amyloid plaque
clearance allowing for self-correction of neurogenesis and synaptogenesis, and
2) direct effects of G-CSF on neural stem/progenitor cells promote neurogenesis
and synaptogenesis. A larger study using multiple proliferative and neurogenic
markers and various time points is needed to more clearly explain the impact GCSF has on the various stages of neurogenesis in the AD mouse brain.
Introduction
Neurogenesis occurs throughout life in the adult brain but differs from
neurogenesis during embryological development. One key difference is that
neurogenesis in the adult mammalian brain is restricted to neurogenic niches, the
subventricular zone (SVZ) of the anterior lateral ventricles and the subgranular
zone (SGZ) of the dentate gyrus (DG) of the hippocampus (HC). The cells of the
SVZ migrate by way of the rostral migratory stream to the olfactory bulb, while
the cells of the SGZ migrate to the granular layer of the DG and integrate into the
hippocampal circuitry.
The existence of adult neurogenesis was first reported by Joseph Altman
(Altman, 1962, Altman and Das, 1965, Altman, 1969) using the tritiated thymidine
method (Messier et al., 1958, Sidman et al., 1959, Messier and Leblond, 1960),
although the idea of gliosis was accepted fairly readily by the scientific
community it was not until later that formation of new neurons in adult brain was
demonstrated experimentally. Using the bromodeoxyuridine (BrdU) doublelabeling method, adult neurogenesis was documented in both mice (Cameron
and McKay, 1998, Kempermann et al., 1998) and humans (Eriksson et al., 1998);
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and after these results were published adult neurogenesis eventually became an
accepted phenomenon.
Another key difference of adult neurogenesis is that it is heterogeneous;
with all the stages of neurogenesis occuring simultaneously (Kempermann et al.,
2004). It is important to note that most of the new born proliferating cells in the
SGZ of the adult HC eventually undergo cell death, instead of differentiation into
mature neurons, which is a rare event (Young et al., 1999, Biebl et al., 2000,
Kempermann et al., 2003). The differentiated mature neurons integrate with
neural circuits of the hippocampus (Dayer et al., 2003).
Cell markers used to assess neurogenesis. The first method used to
assess neurogenesis in the adult brain was tritiated thymidine, which is taken up
by DNA during the S phase of the cell cycle or during cell replication; although
this has the limitation of a short biological/effective half-life in vivo (Messier et al.,
1958). The second method to assess neurogenesis was BrdU uptake by dividing
cells, in which labeling of DNA within the cell was permanent and was passed on
to the progeny of the dividing cell (Nowakowski and Hayes, 2001, Taupin, 2007).
The down side to assessing neurogenesis with BrdU is that it also can label
dying cells, therefore it is important to also look at apoptotic markers (caspase-3
and TUNEL) or proliferative markers (Ki67), when using BrdU alone. Several cell
markers can be used in conjunction with BrdU to better describe the phenotypic
fate of new born cells in the HC, such as immature and mature neuronal markers
(Table 4.1). The different stages of neurogenesis can be defined through the use
of various cell markers; for example as neural progenitor cells begin to
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differentiate into neurons they lose markers such as nestin, but they gain
transient immature neuronal cell markers, such as doublecortin (DCX), and
eventually gain more permanent neuronal cell markers, such as Neuronal Nuclei
(NeuN) (Table 4.2). For this study the cell markers chosen to assess proliferation
and neurogenesis in the adult mouse HC were BrdU and DCX, an immature
neuronal marker.
Factors which influence neurogenesis and synaptogenesis in the
hippocampus. A variety of stimuli can induce proliferation of neural progenitor
cells and promote their differentiation into mature neurons in the adult HC.
Stimuli such as brain injury, physical activity, enriched environment, chronic antidepressant medication treatment, and cytokines can positively influence or
increase hippocampal neurogenesis (Kempermann et al., 1997, van Praag et al.,
1999, Aberg et al., 2000, Malberg et al., 2000, Kernie et al., 2001, Arvidsson et
al., 2002, Jin et al., 2002, Lee et al., 2002, Brown et al., 2003a, Boldrini et al.,
2009). A specific cytokine, G-CSF, has been shown to promote hippocampal
neurogenesis (Schneider et al., 2005, Schabitz and Schneider, 2007, SanchezRamos et al., 2009). Other stimuli such as chronic stress, aging, and depression
can negatively influence or decrease hippocampal neurogenesis (Gould et al.,
1992, Kuhn et al., 1996, Kempermann et al.,1998, Malberg et al., 2000). Aβ
deposition in the brain has also been shown to decrease or impair hippocampal
neurogenesis in AD mouse models (Haughey et al., 2002, Dong et al., 2004,
Wang et al., 2004, Donovan et al., 2006).
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Synatophysin is a pre-synaptic vesicle protein marker, which has been
used to measure synaptogenesis in the hippocampus in both animal models and
human patients (Li et al., 2002). In Tg AD mice, aberrant synaptic terminal
staining has been associated with Aβ deposits (Cracchiolo et al., 2007). A
decline in synaptogenesis or synapse pathology has been correlated with
cognitive decline in both AD patients as well as other forms of dementia
(DeKosky and Scheff, 1990, Terry et al., 1991, Dickson et al., 1995, Terry, 1996,
Scheff and Price, 2003). Aβ deposition may cause a loss of synapses, although a
decrease in synaptophysin and impaired synaptic function may occur prior to Aβ
deposition in various Tg AD mouse models (Hsia et al., 1999, Mucke et al., 2000,
Oddo et al., 2003). G-CSF has been shown to increase synaptophysin density in
both the CA1 and CA3 regions of the HC in an AD mouse model (SanchezRamos et al., 2009).
FACS method as a tool to measure neurogenesis. The current method
to assess proliferation and neurogenesis in the hippocampus is through
immunohistochemistry (IHC), in which BrdU uptake and double-labeling with a
neuronal marker, such as NeuN, is quantified (Kempermann et al., 2003). The
limitation of IHC is that it is laborious and has a low throughput as it can take
several weeks to complete. To resolve the limitation of IHC, a flow cytometry, or
fluorescence activated cell sorting (FACS), method has been used as a robust
and rapid means of BrdU quantification, which has higher throughput screening
for potential treatments that may be used to improve neurogenesis (Bilsland et
al., 2006, Balu et al., 2009). The flow cytometry method of quantification of
103

hippocampal proliferation also has been used by assessment of an in vivo stable
isotope and a proliferation marker, Ki67 (Shankaran et al., 2006, Henry et al.,
2009). The limitation of the FACS method is that the positional information within
DG as well as cell morphological information is lost, which is present in IHC.
When assessing proliferation alone with FACS, it is important to note that
proliferating cells in locations outside of the DG may be counted such as
endothelial cells and oligodendrocytes, although this concern can be alleviated
when double-labeling with a neuronal marker.
Research Rationale
In a previous study done by the Sanchez-Ramos laboratory, G-CSF
treatment of adult mouse HC neural stem/progenitor cells in vitro increased
proliferation measured by incorporation of tritiated thymidine. Moreover, in vivo
studies with a Tg AD mouse model resulted in increased numbers of immature
neurons, Calretinin (CRT) expressing cells in the SGZ of the HC (SanchezRamos et al., 2009). There are other assessments of neurogenesis which were
not performed in those studies, such as BrdU uptake in the DG of the HC and
determination of subsequent differentiation of BrdU birth-dated cells into neurons
expressing immature neuronal markers (DCX) and mature neuronal markers
(NeuN). The use of a variety of proliferative and neuronal markers is important
for a comprehensive understanding of the effect that G-CSF has on hippocampal
neurogenesis. Therefore, the purpose of this study is to further investigate the
effects of granulocyte colony stimulating factor (G-CSF) on hippocampal
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neurogenesis in an AD mouse model as well as a wild-type mouse model, ICR,
using both immunohistochemistry and FACS to assess neurogenesis.
Materials and Methods
Animals for flow cytometry method. ICR mice purchased from Jackson
laboratories were utilized in the study looking at the effect of G-CSF on
neurogenesis in wild-type mice using fluorescence activated cell sorting (FACS)
method. ICR mice were used for each wild-type treatment group (6-8 mice per
group). A total of 10 APP-PS1 double transgenic (Tg) mice (e.g. mice bearing
both APPsw and PS1 mutations) and 15 non-Tg (NT) littermates, ranging from
10-14mo old were utilized in the FACS neurogenesis portion of this study. AD
mice were generated from a cross between F6 generation mice heterozygous for
the mutant APPK670N, M671L gene (i.e. the APPsw, Swedish mutation derived
from Tg2576 mice), and littermate mutant PS1 (6.2 line) mice bearing the M146V
mutation (all mice contained a mixed background of C57B6, B6D2F1, SJL, and
SW). Mice were initially genotyped at the time of weaning and then had a
confirmatory genotyping at 6 weeks of age.
Animals for immunohistochemistry method. Doubly transgenic amyloid
precursor protein (APP) + presenilin-1 (PS1) mice (Holcomb et al., 1998) that
were a cross between mice heterozygous for the mutant APPK670N, M671L
gene (i.e. the APPsw, Swedish mutation derived from Tg2576 mice) (Hsiao et al.,
1996) and littermate mutant PS1 (5.1) line) mice bearing the M146L mutation
(Duff et al., 1996). Mice were initially genotyped at the time of weaning and then
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had a confirmatory genotyping at 6 weeks of age. A total of 11 APP-PS1 double
Tg mice and 8 non-Tg (NT) littermates were utilized in the immunohistochemistry
portion of this study.
All mice, for both methods, were housed and maintained in standard
laboratory cages in a temperature and humidity controlled room in a specific
pathogen free facility under a 12-h light/dark cycle with light onset at 6:30 AM,
with ad libitum access to rodent chow and water. All experiments conformed to
guidelines for the ethical use of animals as provided by the Association for the
Assessment and Accreditation of Laboratory Animal Care, International
(AAALAC #000434). The protocol was approved by the IACUC of the University
of South Florida.
G-CSF dose and administration schedule of IHC AD mouse group. GCSF, a natural human glycoprotein, exists in two forms of a 174-and 180-aminoacid-long protein of molecular weight 19,600 g per mol. The more-abundant and
more-active 174-amino acid form has been used in the development of
pharmaceutical products by recombinant human DNA (rhDNA) technology.
Filgrastim (Neupogen®, Amgen, Inc., Thousand Oaks, CA, USA), one of three
proprietary G-CSF compounds, was utilized in the present study. The dose of GCSF (250 μg/kg x 8 doses) administered in the present study was determined
based on the dose used in the previous study published by the Sanchez-Ramos
laboratory (Sanchez-Ramos et al., 2009). In that study, G-CSF significantly
decreased Aβ plaque formation, increased microgliosis and improved
neurogenesis and behavior in radial arm water maze (RAWM). This dose is lower
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than that reported to be effective in mobilizing bone marrow in a rat model of
stroke (300μg/kg x 10 days), but higher than that utilized by others in rodent
models of stroke (Schabitz et al., 2003, Six et al., 2003, Solaroglu et al., 2006)
and in a published report on the treatment of memory impairment in a mouse
model of AD (50 μg/kg s.c. for 5 days) (Tsai et al., 2007).
The APP/PS1 and NT were 8mo old at the time of G-CSF treatment. The
schedule of administration of G-CSF was one subcutaneous (s.c.) injection every
other day (qod) over two and a half weeks. G-CSF was diluted in 5% dextrose at
a 1/20 dilution as recommended by the manufacturer (Amgen, Inc.). Vehicle (5%
dextrose) was administered to control groups for both Tg and NT mice.
G-CSF dose and administration schedule in AD & ICR mice for FACS
neurogenesis method. The dose of G-CSF (250 μg/kg x 6 doses) administered
in FACS neurogenesis model was based on the dose used in the previous study
published by the Sanchez-Ramos laboratory (Sanchez-Ramos et al., 2009). The
schedule of administration of G-CSF was one subcutaneous (s.c.) injection every
day over 6 days, which began when the ICR mice were 6 mo old and the
APP/PS1 and NT mice were 10-14 mo old. G-CSF was diluted in 5% dextrose at
a 1/20 dilution as recommended by the manufacturer (Amgen, Inc.). Vehicle (5%
dextrose) was administered to control groups for Tg AD, NT and ICR mice.
BrdU preparation and administration. BrdU solution was prepared at
10mg/ml at pH 7.4 in 1X PBS. Mice received an intraperitoneal (i.p.) injection of
75 mg/kg BrdU twice daily, 6:30AM and 6:30PM, for the last 3 days of G-CSF
treatment regimen in the AD mouse model IHC study. ICR mice and APP +PS1
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or NT mice utilized for the FACS neurogenesis method received an i.p. injection
of 100 mg/kg BrdU daily on the last two days of G-CSF treatment.
FACS neurogenesis: preparation of cells and flow cytometry. After
the mice were sedated with Nembutal and perfused with 0.9% NaCl, their brains
were removed and halved along the midline. The hippocampi of the halves to be
analyzed by flow cytometry were dissected out and finely minced. Each
hippocampus was dissociated into a single cell solution using MACS cell
dissociation kit (Miltenyi Biotech) and fixed overnight in 75% ethanol. After
fixation the cells were washed in PBS and the DNA denatured in 2N HCl/ 5%
Triton-X and neutralized in 0.1M borate buffer. For fluorescence labeling, each
single cell solution was incubated for 30 minutes at room temperature in a
cocktail containing FITC-conjugated mouse anti-BrdU antibody (BD Bioscience,
1:5), fluorescently conjugated mouse anti-NeuN (Chemicon, 1:25), 1% BSA, and
1.5% Tween 20 (Sigma). Anti-NeuN was conjugated using Dylight 405
Microscale Antibody Labeling Kit (Thermo Scientific). Finally, the cells were
washed, re-suspended in 1mL of 10μg/ml propidium iodide (PI) (Sigma), and
analyzed using the BD Aria cell sorter. Only diploid (2N) cells of the cell cycle
were gated out of the PI positive cells (Baisch et al., 1975). The diploid cells were
then “backgated” to eliminate debris. To analyze cell proliferation by BrdU
incorporation, a FITC fluorescence vs. PI-diploid cells scatter plot was generated.
The FITC positive cluster was further gated and visualized in a FITC
fluorescence vs. Alexa 405 fluorescence to determine the number of double
positive (Brdu+/NeuN+) cells in the BrdU positive cluster. Gates were set using
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negative controls obtained by incubating samples without the fluorochrome in
question.
Immunohistochemistry. Mice were euthanatized two weeks after the last
treatment of G-CSF using an intraperitoneal (i.p.) injection of 0.1ml somnasol,
then received a 100-200 unit injection of heparin into the heart, followed by
transcardial perfusion of 0.9% saline (~40ml/mouse) followed by four percent
paraformaldehyde (PFA) (~20ml/mouse). Brains were then removed from skull
and fixed in 4% PFA for 24h, the right hemisphere of the brain was transferred to
30% sucrose solution for 4 days for immunofluorescence. After the 25% sucrose
solution the right hemisphere was frozen in isopentane on dry ice then
transferred to -80˚C freezer. The right hemisphere was then transferred to the
cryostat (set at -20˚C) (Leica, Germany) one hour prior to sectioning the brains to
allow them to equilibrate in temperature, then brains were sectioned coronally
using the cryostat at 30μM in a 1:6 series and stored in 24-well plates in a
cryoprotectant/anti-freeze solution at (-20 to -18˚C). For those sections
undergoing immunohistochemistry for BrdU, sections were first denatured using
2N HCl for 1h at room temperature and neutralized in 0.15M borate buffer for
15min. Prior to immunofluorescence staining sections then were washed three
times in 1X PBS then placed in a blocking solution (PBS+ 10% normal donkey
serum, 3% bovine serum albumin (BSA), & 10% Triton-X 10X) for one hour at
4˚C on maxi rotator. Sections were then incubated for 24 hours at 4˚C in a
primary antibody cocktail of rat anti-BrdU (1:75, AbD Serotec, Raleigh, NC) plus
mouse anti-NeuN(1:100, Millipore, Billerica, MA), or a primary antibody cocktail
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of rabbit anti-DCX (1:2000, abcam, Cambridge, MA). Sections were washed in
PBS and incubated for one hour at room temperature in a secondary antibody
cocktail of donkey anti-rat Alexa Fluor 594 (1:1000, Invitrogen, Grand Island,
NY) plus donkey anti-mouse IgG Alexa Fluor 488 (1:1000, Invitrogen, Grand
Island, NY), or a secondary antibody cocktail of donkey anti-rabbit Alexa Fluor
594 (1:1000, Invitrogen, Grand Island, NY),and coated with Vectashield
mounting medium without or with DAPI (Vector Laboratories, Burlingame, CA).
Labeled cells were visualized with fluorescence microscopy (IX2 inverted
microscope; Olympus, Tokyo, Japan) using appropriate filters. Cells in the
subgranular zone of the dentate gyrus were counted via microscope by a single
blinded examiner. Digital images were captured with the DP-70 digital camera
system (Olympus).
The left hemisphere was transferred from 4% PFA then routinely
embedded in paraffin with 24 h processing. For paraffin sectioning, five coronal
sections (per set) with a 150 μm interval were cut at a thickness of 5 μm in
hippocampus (HC) and entorhinal cortex (EC), bregma -2.92 to -3.64 mm
(Paxinos G, 2001). Four sets of five sections from HC and EC were prepared for
analyses of Aβ plaque and Iba1 (ionized calcium-binding adapter molecule 1).
Immunohistochemical staining was performed following the manufacturer’s
protocol using a Vectastain ABC Elite kit (Vector Laboratories, Burlingame, CA,
USA) coupled with the diaminobenzidine (DAB) reaction, except that the
biotinylated secondary antibody step was omitted for Aβ immunohistochemical
staining. The following primary antibodies were used for immunohistochemical
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staining: a biotinylated human amyloid-β monoclonal antibody (clone 4G8; 1:200,
Covance Research Products, Emeryville, CA, USA), an Iba-1 polyclonal antibody
(1:1000, Wako, Osaka, Japan), and rabbit synaptophysin polyclonal antibody
(undiluted, DAKO, Carpinteria, CA, USA).
Quantification of Immunofluorescence. BrdU+ or DCX+ labeled cells
were estimated using every 6th section taken throughout the hippocampus
(every 180 microns). To avoid counting partial cells a modification to the optical
dissector method was used so that cells on the upper and lower planes were not
counted. The number of BrdU+ or DCX+ cells counted in every 6th section was
multiplied by 6 to get the total number of BrdU+ or DCX+ cells in the SGZ of the
hippocampus (Shors et al., 2002).
Quantification of biotinylated immunohistochemistry. Images of DAB
stained sections were acquired as digitized tagged-image format files to retain
maximum resolution using an Olympus BX60 microscope with an attached digital
camera system (DP-70, Olympus), and digital images were routed into a
Windows PC for quantitative analyses using SimplePCI software (Compix, Inc.
Imaging Systems, Cranberry Township, PA, USA). Images of five sections (each
5 μm thick and 150 μm apart) were captured from serially sectioned EC and HC
and a threshold optical density was obtained that discriminated staining from
background. Each anatomic region of interest was manually edited to eliminate
artifacts. For Aβ and Iba1 (microgliosis) burden analyses, data are reported as
the percentage of labeled area captured (positive pixels) divided by the full area
captured (total pixels). Bias was eliminated by analyzing each entire region of
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interest (HC and EC) represented by the sampling of five sections per region.
Stereological equipment was not used. To evaluate synaptophysin
immunostaining, after the mode of all images was converted to gray scale, the
average optical density of positive signals from each image was quantified in the
CA1 region of HC as a relative number from zero (white) to 255 (black) and
expressed as mean intensity of synaptophysin immunoreactivity. Each analysis
was done by a single examiner blinded to sample identities.
Statistical Analysis. An unpaired two-tailed t-test was used to evaluate βamyloid burden, Aβ 1-40 and 1-42 plasma levels, and FACS analysis in ICR
mice. Two-way analyses of variance (ANOVA) was used to evaluate the effects
of G-CSF (treatment) on immunohistochemical analyses and FACS analysis in
APP/PS1 and NT mice. All statistical analyses were determined significant at the
0.05 alpha level. When appropriate, post hoc analysis was used, such as the
Bonferroni, to isolate effects of G-CSF treatment. Data was presented as mean ±
standard deviation (SD).
Results
Effect of G-CSF on neurogenesis in a wildtype (ICR) and AD Tg
mouse model as measured via FACS. Traditionally neurogenesis is measured
by analyzing either immature neuronal markers, such as DCX (Brown et al.,
2003b), or new cells of neuronal lineage, i.e. cells birth-dated by BrdU that
express NeuN (Kempermann et al., 2003), through histological analysis using
immunohistochemistry (IHC) to identify these positive cells within the DG of the
HC. Due to the time and labor expenditure needed to perform IHC, newer
112

methods to assess neurogenesis were of interest, such as FACS which can be
completed in a matter of a few days (Bilsland et al., 2006, Spoelgen et al., 2011).
Particularly of interest was the effect of G-CSF on neurogenesis in normal or
wild-type mice (ICR), as well as in an AD mouse model (APP/PS1 and NT). Mice
received 6 days of s.c. G-CSF followed by i.p. BrdU injections daily on the last
two days of G-CSF treatment. Then, the animals were euthanatized two weeks
following last injection of G-CSF to allow time for differentiation of new born cells
within the DG of the HC. In the wild-type ICR mice there was a significant
increase in both BrdU+ cells in the HC (p=0.03) and in BrdU+NeuN+ cells in the
HC (p=0.004) (Figure 4.1). In the APP/PS1 and NT mice there was no significant
increase in BrdU+ cells (data not shown) or in BrdU+NeuN+ cells in the HC
(Figure 4.2). However, there was a slight increase in BrdU+NeuN+ cells in the
HC of the G-CSF treated APP/PS1 mice that almost reached significance
(p=0.052).
Effect of G-CSF on proliferation and neurogenesis in AD Tg mouse
model (as measured via IHC). 8mo NT or APP/PS1 mice received G-CSF or
vehicle s.c. injections (8 inj qod); these mice received BrdU injections twice daily
during the last two days of G-CSF treatment in order to measure the amount of
BrdU uptake, or proliferation, in the subgranular zone (SGZ) of the DG in the HC.
G-CSF did not significantly increase BrdU+ counts in either the NT or Tg
APP/PS1 mice in the SGZ of the HC (Figure 4.3). An immature neuronal marker,
DCX, was also measured in the SGZ of the HC in this group of mice and it was
found that APP/PS1 vehicle DCX counts were significantly lower than that of
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either vehicle or G-CSF treated NT DCX counts, and treatment with G-CSF
increased DCX counts in the SGZ of the HC of Tg mice to that of NT DCX levels
(Figure 4.4).
G-CSF increases synaptogenesis in the CA1 region of the
hippocampus in a NT and Tg AD mouse model. A decline in synaptogenesis
is thought to be a robust correlate of AD-like cognitive decline. Therefore,
synaptophysin density using optical density was measured in the CA1 region of
the HC in both NT and Tg AD mice treated with G-CSF or vehicle (Li et al.,
2002). G-CSF treatment in both the NT and Tg AD groups resulted in a
significant increase of synaptogenesis in the CA1 region of the HC (Figure 4.5).
This data is similar to the results found in a previous study by Dr. SanchezRamos laboratory (Sanchez-Ramos et al., 2009).
Effects of G-CSF on β-amyloid burden, β-amyloid plasma levels, and
microgliosis in the AD mouse brain. Since irradiation and bone marrow
transplantation is a factor that may influence effects of G-CSF, it is important to
compare G-CSF effects on amyloid burden and microgliosis in non-chimeric Tg
APP/PS1 with those parameters in chimeric Tg APP/PS1 mice (Chapter 3).
Hence, the effect of G-CSF on β-amyloid burden, β-amyloid plasma levels and
microgliosis was also assessed in this study; NT (n=8) and Tg AD mice (n=11)
were treated with s.c. injections of G-CSF or vehicle every other day for a total of
8 injections. Treatment with G-CSF resulted in a significant decrease in the
percentage β-amyloid burden (4G8) in the HC, but not the EC, in the Tg AD mice
(two-tailed unpaired t-test P<0.001) (Figure 4.6A). There was no significant
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change in either Aβ 1-40 or Aβ 1-42 plasma levels with G-CSF treatment (Figure
4.6B). Total microgliosis was measured using the marker Iba1, which labels both
resting and activated microglia, in both the HC and the EC. There was a
significant genotypic effect on microgliosis, in which Tg AD mice had significantly
increased levels of microgliosis in the HC and EC in comparison to the NT
littermates (two-way ANOVA, P<0.0001). G-CSF treatment significantly
increased microgliosis in Tg AD mice in the HC, but not the EC, although did not
have an effect on NT AD mice in either the HC or the EC (two-way ANOVA,
P<0.01) (Figure 4.6C).
Discussion
G-CSF has been shown to directly augment proliferation of neural stem
cells (NSC) in hippocampal mouse cell cultures in vitro and increase formation of
new neurons in the SGZ of the HC in vivo (Sanchez-Ramos et al., 2009). This
previously unrecognized effect promoted the further investigation of the
neurogenic effects of G-CSF in adult mouse models. Only one neuronal marker
was assessed in the previous study, Calretinin, a transient immature neuronal
marker, it was therefore of interest to see if G-CSF also positively impacted other
proliferative and neurogenic markers in the HC. It was of interest to see if this
increase in neurogenesis elicited by G-CSF occurred only in an AD mouse
model, or whether it could also be observed in a normal, or wild-type, mouse
model.
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The FACS method is a rapid yet robust method for measuring
hippocampal proliferation and neurogenesis (Bilsland et al., 2006, Spoelgen et
al., 2011). Using this approach, a significant increase in proliferation (BrdU+) and
neurogenesis (BrdU+NeuN+) was observed in the normal mouse (ICR), but there
was only a slight increase of hippocampal neurogenesis (BrdU+NeuN+ cells) in
the G-CSF treated APP/PS1 mice (p=0.052).
During hippocampal neurogenesis there is an initial production of neural
progenitors that may or may not differentiate into mature neurons as many of
these cells undergo apoptosis prior to differentiation. Therefore it may not be that
G-CSF is increasing the number of neural stem/progenitor cells, but is directing a
greater percentage of those progenitors to differentiate into a neuronal
phenotype as opposed to choosing apoptosis or differentiation into a glial
lineage. In the older AD mice, G-CSF did not increase proliferation unlike the
stimulation of BrdU incorporation observed in younger normal mice. An increase
in new neuron formation was noted in both normal and AD mice, but the increase
was small in AD mice.
Another interesting observation is the increase in microgliosis as well as
the decrease in amyloid plaque burden in the hippocampus of APP/PS1 mice
after G-CSF treatment. Aβ is known to be toxic to neurons, therefore by
decreasing the amount of Aβ burden in the hippocampus neurons are better able
to proliferate, differentiate, and project from the dentate gyrus and form neural
circuits through synaptogenesis. So not only may G-CSF have the ability to act
directly on neurons, as they express the G-CSFR, but by assisting in amyloid
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clearance, the micro-environment of the dentate gyrus of the hippocampus
becomes more conducive for neurogenesis.
Due to the slight increase in neurogenesis in an AD mouse model using
both the flow cytometry and immuhistochemical methods, it would be worth
pursuing further studies on the effect of G-CSF on neurogenesis with a larger N
in the same cohort of mice simultaneously with both methods, FACS and IHC. It
will also be important to assess a broader range of neurogenic cell markers, both
proliferative, immature neurogenic, and double-labeled mature neurogenic, at
various time points (2 weeks and 4 weeks) after G-CSF treatment. One should
be able to determine which stages in the determination of neuronal fate are most
sensitive to the influence of G-CSF.
Due to the small N in this study a power analysis was performed to
determine the sample size of animals that would be necessary in future studies
to detect a difference in neurogenesis based on the current IHC studies
variability. It was determined N of 14 animals per group is necessary to detect a
difference between the means with an alpha=0.05 and beta=0.80.
Summary
We have generated evidence that G-CSF has effects on cells of the CNS
that result in microgliosis which appears to improve amyloid plaque clearance
allowing for self-correction of neurogenesis and synaptogenesis. G-CSF was
also shown to directly promote neurogenesis and synaptogenesis. A larger study
using multiple proliferative and neurogenic markers and various time points is
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needed to more clearly explain the impact G-CSF has on the various stages of
neurogenesis in the AD mouse brain. Taken together, with the in vitro and
chimeric AD mouse experiments in this present study it is clear that G-CSF has
beneficial effects in an AD mouse model although the exact mechanism of action
remains unclear, but is most likely multifaceted.
Table 4.1. Cell markers used to assess phenotypic fate of neural progenitors.
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(A)
(B)
Figure 4.1. Effect of G-CSF on neurogenesis in the hippocampus of normal mice (measured
via FACS). ICR mice were treated with 250μg/kg s.c. for 6 days with daily injection of BrdU
100mg/kg on the last two days of G-CSF treatment. Mice were euthanatized two weeks
later. (A) G-CSF significantly increased the number of BrdU+ (n=7 mice per group, unpaired
two-tailed t-test, *P=0.03),as well as (B) BrdU+NeuN+ in the hippocampus of normal ICR
mice (n=7 mice per group, unpaired two-tailed t-test, *P=0.004), which shows an
improvement in both hippocampal proliferation and neurogenesis with G-CSF treatment.
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Figure 4.2. Effect of G-CSF on hippocampal neurogenesis of NT and Tg APP/PS1
AD mice (measured via FACS). APP/PS1 and NT mice were treated with 250μg/kg
s.c. for 6 days with daily injection of BrdU 100mg/kg on the last two days of G-CSF
treatment. Mice were euthanatized two weeks later (error bar represents SEM). GCSF did not cause a significant increase in BrdU+NeuN+ cells in the hippocampus,
although there was an increase with G-CSF treatment in APP/PS1 with a trend
towards significance (n=5-8 mice per group, one-way ANOVA).
(A)

(B)
Figure 4.3. Effect of G-CSF on proliferation in the dentate gyrus (DG) of NT or APP/PS1
Tg mice. 8mo NT or APP/PS1 mice received G-CSF or vehicle s.c. injections (8 inj qod).
(A) G-CSF did not significantly increase BrdU+ counts in either the NT or Tg AD mice,
although there was a significant genotypic effect in which there are greater BrdU counts
in NT mice (n=3 mice per group, two-way ANOVA, genotype p=0.0119, treatment
p=0.1278); (B) BrdU positive cells in the subgranular zone of the DG in Tg AD mice (20x
image).
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(A)

(B)
Figure 4.4. Effect of G-CSF on neurogenesis in the dentate gyrus (DG) of NT or
APP/PS1 Tg mice. 8mo NT or APP/PS1 mice received G-CSF or vehicle s.c.
injections (8 inj qod). (A) APP/PS1 vehicle DCX counts were significantly lower than
that of vehicle or G-CSF treated NT mice (n=3 mice per group, two-way ANOVA,
* genotype p=0.0243, treatment p=0.0163), and G-CSF treatment increased DCX
counts in Tg mice to NT levels; (B) Doublecortin (DCX+) positive cells in the
subgranular zone of the DG (20X).
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(A)

(B)

Figure 4.5. Effect of G-CSF on synaptogenesis in the
CA1 region of the hippocampus in NT or APP/PS1 Tg
mice. 8mo NT or APP/PS1 mice received G-CSF or
vehicle s.c. injections (8 inj qod). (A) G-CSF
significantly increased synaptogenesis in the CA1
region in both NT & APP/PS1 mice (n=4 mice per
group, two-way ANOVA, *=P<0.001) (B)
Synaptophysin (SP) positive staining in the CA1
region of the hippocampus (40X).
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Figure 4.6. Effect of G-CSF on β-amyloid burden, Aβ plasma levels and microgliosis in
NT & Tg AD mice. (A) G-CSF significantly decreased amyloid plaque burden (4G8) in
the hippocampus , but not the entorhinal cortex, in Tg AD mice (n=4 mice per group,
unpaired two-tailed t-test, *=P=0.002); (B) G-CSF did not have an effect on plasma Aβ
levels; and (C) G-CSF significantly increased microgliosis in the hippocampus , but not
the entorhinal cortex, in Tg AD mice (n=4 mice per group,two-way ANOVA, *=P<0.01).
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Chapter 5: Final Discussion
In the preceding chapters, the effects of G-CSF on peripheral cells of bone
marrow origin and cells of the central nervous system were investigated both
in vitro and in vivo. The overall objective was to elucidate the mechanism(s)
of action responsible for the previously reported beneficial actions of G-CSF
in an AD mouse model (Tsai et al., 2007, Sanchez-Ramos et al., 2009).
For the in vitro studies, cell lines were chosen to model human monocytes
(THP-1) and human neurons (SH-SY5Y). Studies of radio-labeled ligand (125IGCSF) binding to the cognate GCSF-receptor resulted in saturation curves
with distinctly different shapes (hyperbolic in the monocytes; sigmoid in the
neuronal line). The pharmacokinetic binding parameters were also distinctly
different. The monocytic cell line exhibited a greater binding affinity (lower Kd)
while the neuronal cell line revealed a greater Kd, Bmax and receptor density.
The neuronal line exhibited cooperative binding kinetics (Hill coefficient ~2)
while the monocytic line revealed linear binding (Hill coefficient ~1).
The marked differences in G-CSF binding kinetics to monocytic and
neurnal cells observed in vitro do not easily fit the in vivo observation that
levels of G-CSF in brain are significantly lower than those in blood in
untreated Alzheimer’s Disease. Theoretically, it would be expected that the
Kd in neurons of the brain would be much lower than that of monocytes so
that the normally lower levels of brain G-CSF could interact with receptors
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expressed on neurons. However, during severe inflammatory processes in
brain (e.g. meningitis), levels of G-CSF are known to increase to
concentrations higher than in the blood. In those situations, there would be
high enough concentrations of endogenous G-CSF to activate neuronal GCSF receptors. However, administration of exogenous G-CSF at high doses
to patients with AD might result in sufficiently high levels of G-CSF in brain, at
least transiently, to activate receptors borne on neurons and neural
stem/progenitor cells.
Further comparison of the monocytic and neuronal cell lines showed antiapoptotic proteins (PKCδVIII and Bcl2) in the neuronal cell line were upregulated at lower concentrations (100ng/mL) of G-CSF than in the monocytic
cell line (200ng/mL). This greater degree of up-regulation of anti-apoptotic
proteins occurs in neuronal cells which have a greater number of receptors
per cell despite lesser binding affinity for the ligand. It is likely that the
neuronal cell line has different number or amount of the G-CSFR effector
molecules, cytosolic tyrosine kinase, or that it has a greater proportion of
spare receptors, which would allow a full biological response even when only
a small proportion of the total receptors are bound.
It was of interest to assess if the beneficial effects of G-CSF on AD mice
seen in previous studies (Tsai et al., 2007, Sanchez-Ramos et al., 2009)
could be attributed to an increase in the number of circulating bone marrow
derived monocytes (or pro-monocytes) infiltrating the brain parenchyma. To
objectively study this potential mechanism, the migratory properties of a
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monocyte cell line (THP-1) were examined in a migration chamber system.
G-CSF did not change migratory properties of monocytes in vitro, neither
through improved adhesion in cell culture, nor through migration through a
micropore membrane.
However, we showed that G-CSF treatment increased the proportion of
mouse GFP+BM cells that express a monocytic marker (CD11b) and
significantly stimulated DNA synthesis in the human monocytic cell line.
These results are consistent with the observation that G-CSF treatment
(10µg/kg/day) of AD patients for five days increased the absolute number of
circulating monocytes (and blood stem/progenitor cells) in subjects with AD
(Sanchez-Ramos J, 2012). These observations in the transgenic GFP+
mouse and AD patients suggest that the total amount of bone marrow derived
monocytes or pro-monocytes infiltrating the brain parenchyma in vivo might
occur through “mass action” or an increase in total circulating monocytes, and
not through improved migratory properties. A caveat to this statement is that
absence of changes in migratory capacity of an immortalized monocytic/promonocytic cell line in vitro may not reflect what happens to authentic
monocytes in vivo.
In the irradiated chimeric GFP and non-irradiated APP/PS1 AD mice there
was a significant increase in microgliosis and reduction of amyloid burden in
the hippocampus with G-CSF treatment, but the infiltration of monocytes did
not contribute to this increase in microgliosis as there were no GFP labeled
bone marrow derived cells found in the brain parenchyma of the chimeric AD
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mice. Although GFP labeled cells were found in the microvasculature of the
brain as well as in the choroid plexus, the proportion of GFP cells in the
microvasculature of the hippocampus and entorhinal cortex was not
increased with G-CSF treatment. This part of the research had several
limitations that will require further investigation. Although inspection of a blood
smear from chimeric mice transplanted with GFP+ bone marrow was
performed to ascertain “successful” engraftment, the percentage of GFP+
cells in the chimeric mice was not quantified from blood samples before
administration of G-CSF or after euthanasia. It is possible that the
engraftment of the GFP+ donor cells was minimal and the host bone marrow
stem cells that survived irradiation repopulated the marrow to a greater extent
than the GFP+ cells. If the percentage of GFP+ monocytic cells in the
circulation were to be very low, it would result in an underestimation or failure
to detect monocytic cell infiltration.
Nevertheless, failure to observe GFP+ cells in the brains of AD mice in
these experiments suggests that it is not the action of G-CSF on the BM or
the circulating monocytes that result in an increase in microgliosis in both
irradiated chimeric and non-irradiated APP/PS1 mice. It is most likely due to
the direct action of G-CSF on endogenous microglia, which have also been
known to express the G-CSFR. It will be important to examine the effects of
G-CSF on microglial proliferation and phagocytosis of Aβ in vitro in future
studies, as it is likely that the increase in microgliosis results in improved
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phagocytosis of amyloid plaques resulting in the increase in amyloid burden
clearance that was seen in vivo with G-CSF treatment.
After observing the stimulatory effects of G-CSF on DNA synthesis and
proliferation, enhancement of viability, and up-regulation of anti-apoptotic
proteins in the human neuronal cell line, the next step was to investigate the
in vivo neurogenic effects of G-CSF in non-irradiated mice (both in normal
and in a Tg AD mouse model). In normal mice (ICR) using fluorescence
activated cell sorting (FACS), both hippocampal proliferation (BrdU) and
hippocampal neurogenesis (BrdU/NeuN) were significantly improved with GCSF treatment, although FACS analysis did not reveal similar increases in the
AD mouse model. In a non-irradiated AD mouse model using
immunohistochemistry, G-CSF increased doublecortin (DCX) expressing cells
(or immature neurons) and increased synaptophysin-density in the CA1
region of the hippocampus indicating enhanced neurogenesis and
synaptogenesis in this APP/PS1 mouse model. The stimulation of
neurogenesis and synaptogenesis could be attributed to 1) the direct action of
G-CSF on hippocampal neural progenitors, which was consistent with the in
vitro data in the human neuronal cell line, or 2) the direct action of G-CSF on
endogenous microglia which reduces amyloid burden and provides an
improved neurogenic environment. Therefore future studies comparing the
effects of G-CSF on neural progenitor cells and microglia will be important to
elucidate the contribution of each of the cell types to the beneficial effects
seen with G-CSF treatment in an AD mouse model.
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In summary, these studies were designed to explore the mechanism(s) of
action of G-CSF responsible for a) enhancement of cognitive performance in
a Tg AD mouse model, b) reduction of amyloid burden, c) increased
microgliosis and d) stimulation of hippocampal neurogenesis. Working with
cellular models of monocytic and neuronal cell lines, we found that a) G-CSF
interacts with its cognate receptor with different binding kinetics and with
greater affinity for the monocyte G-CSFR, b) the number of G-CSF receptors
in neurons is greater than in monocytes, and c) the anti-apoptotic response in
neurons occurs at lower concentrations of G-CSF than in monocytes. From
these experiments we infer that neuronal G-CSF receptors are activated only
when levels of G-CSF ligand in brain are equal to or higher than G-CSF levels
in blood (as in severe inflammation, injury to blood brain barrier or after
administration of high doses of G-CSF as a therapeutic agent). Moreover, GCSF appeared not to enhance migratory capacity of monocytes so it is
unlikely that the increased microgliosis observed in the earlier studies in Tg
AD mice is solely attributable to increased infiltration of monocytes into brain.
From these observations, we infer that the direct effects of G-CSF on
microglia is most likely to be responsible for microgliosis and decreased
amyloid burden.
From a translational perspective, these findings provide an impetus to
develop G-CSF as a pro-cognitive agent in diseases associated with decline
in hippocampal neurogenesis, such as AD and other dementing illnesses.
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